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The ABC transporter P-glycoprotein (Pgp) and membrane permeability are 
determinant factors for absorption and disposition of xenobiotics. These studies 
investigated the effects of potential modulators of Pgp and/or membrane function on the 
disposition, bioavailability and bioaccumulation of environmentally relevant 
pharmaceuticals, tetracycline and ivermectin, and the carcinogen benzo[a]pyrene in 
catfish. The pesticide dieldrin and surfactant linear alkylbenzene sulfonate (LAS) were 
selected as mixture components thought to have potential interactions with these 
determinants of disposition. Initial in situ experiments demonstrated dieldrin and 
tetracycline both significantly inhibited biliary excretion of Pgp prototypic substrate 
Rhodamine-123 in isolated perfused livers. Further, dieldrin (20µM) reduced movement 
of 3H-tetracycline (8.8nM) into bile (55%) to a greater extent than Pgp prototypic 
competitive inhibitor verapamil. In contrast to inhibitory effects in situ, a 4-week dietary 
dieldrin preexposure (0.1mg/day/kg body weight) increased plasma clearance (17%) and 
reduced tissue concentrations of 3H-tetracycline equivalents (parent and metabolites) for 
a single intra-aortic administration of 3H-tetracycline (8.31µg/kg body weight) in catfish. 
A 23% increase in the immunoreactive Pgp level in the hepatic membranes following 
chronic dietary dieldrin exposure was correlated with in vivo changes in disposition. 
Additional in situ studies demonstrated LAS treatments (1, 5, and 20µM) reduced 
movement of Rhodamine-123 (1µM) into bile in isolated perfused livers (18.6, 38.1 and 
66.7%, respectively). Fluorescent anisotropy measurements of the corresponding hepatic 
membranes showed a 29.7% decrease (increase in membrane fluidity) at the 1µM LAS 
concentration, with little additional change evident at higher concentrations. In sequential 
in vivo experiments, following six daily diet administrations of 3H-ivermectin (10 
 viii
 ix
µg/day/kg body weight) or 3H-benzo[a]pyrene (40 µg/day/kg body weight) starting on 
day 7 during a twelve-day waterborne LAS exposure (0, 100 and 300µg/l), 3H-ivermectin 
and 3H-benzo[a]pyrene equivalent remaining in catfish and their blood and tissue 
concentrations increased in a dose-dependent fashion with increasing LAS concentrations. 
The first study indicates dieldrin inhibited Pgp transport at the high concentration with 
the inductive effect upon Pgp expression predominating at the low concentration 
exposures in vivo. Findings of the second study suggest that LAS at environmental 
concentrations altered membrane permeability and/or transporter function so to increase 
bioaccumulation of other xenobiotics from the diet.  
 
INTRODUCTION 
A wide range of anthropogenic contaminants are found in the aquatic 
environment. Fish living in those environments may be exposed to various contaminants 
as well as pharmaceutical drugs entering the water from domestic, agricultural and 
aquaculture applications. Many factors are known to influence bioavailability and 
bioaccumulation of these chemicals in fish (Leblanc, 1995; Ivanciuc et al., 2006). 
Membrane permeability is generally considered as a key determinant in the extent of 
absorption, distribution and elimination of chemicals in the body. Exposure concentration 
and duration, compound lipophilicity and the susceptibility of the chemical to 
biotransformation also play a role in dictating contaminant body burdens. Recently, 
studies in mammals suggest that Phase III transport processes by ABC (ATP binding 
cassette) transporters such as P-glycoprotein (Pgp) may have a significant effect on 
xenobiotic bioavailability and bioaccumulation (Kurata et al ., 2002; Liu and Hu, 2000; 
Fromm, 2000; Shitara, 2006).  
Membrane permeability may affect the transfer of the xenobiotics in the body in 
various ways (Malkia et al., 2004). The gastrointestinal tract provides an efficient barrier 
to the permeability of some xenobiotics, while chemicals are readily permeable as a 
function of physicochemical characteristics of the compound and the membrane (Smith et 
al., 1996; Lin, 2003).  In addition, the gastrointestinal tract is lined with transporters 
which “pump” absorbed xenobiotics back into the intestinal lumen. Such an action 
reduces systemic bioavailability in a compound specific manner. Increases in 
gastrointestinal tract membrane permeability may facilitate xenobiotic uptake from the 
diet as a means to circumvent the transport barrier function. In the liver, the compound 
enters into the hepatocyte from the blood and is actively transported from the hepatocyte 
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across the canalicular membrane into bile for clearance of the compound. In this case, 
increased membrane permeability in the liver short-circuits active transport and clearance 
by allowing the compound to move from the higher concentration of the bile back into 
the hepatocyte. This action promotes compound retention in the body. 
The transfer of xenobiotics in the body is generally controlled by their 
permeability across tissue membranes. However, increased diffusion across the biological 
membranes is not always predicative increased permeability due to the contribution of 
active efflux transporters (Ayrton and Morgan, 2001). Pgp, an ATP-dependent 
transmembrane transporter, is best known for efflux movement of various therapeutic 
agents actively out of the cell. First observed and overexpressed in multidrug resistance 
(MDR) tumor cells, Pgp has been found in normal mammalian tissues, especially in the 
luminal face of intestine, the biliary canalicular membrane of hepatocytes, the apical 
surface of epithelial cells of kidney and as part of the blood-brain barrier (Wacher et al., 
2001; Frohlich et al., 2004). Owing to its location in organs of absorption, the blood-brain 
interface and organs of elimination, the functionality of the Pgp transporter in 
conjunction with membrane permeability may be a significant factor in compound 
absorption, distribution and elimination.    
A Pgp-mediated multixenobiotic resistance (MXR) mechanism has also been 
associated with modulation of xenobiotic bioavailability and bioaccumulation in aquatic 
organisms (Kurelec, 1995). Fish have been shown to have Pgp “like” protein which 
displays a high degree of sequence homology (Chan et al., 1992), a similar tissue 
distribution pattern (Kleinow et al., 2000), and transport function consistent with those 
known in mammals (Schramm et al., 1995; Smital et al., 2004). One of the most 
remarkable features for the Pgp transporter in both mammals and fish is its broad 
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substrate specificity. Substrates which have been identified include various therapeutic 
agents, certain food constituents (Balayssac et al., 2005), hormones (Leslie et al., 2005),  
as well as a number of contaminants (Galgani et al., 1996; Toomey et al., 1996; Bard, 
2000; Leslie et al., 2005). With the exception of moderate hydrophobicity or 
amphiphilicity, few common chemical characteristics have been identified among Pgp 
substrates (Gottesman and Pastan, 1993; Kusuhara et al., 1998).   
 A variety of environmental xenobiotics have been shown to inhibit Pgp transport 
activity either as competitive or noncompetitive inhibitors. Four hydrophobic pesticides 
including dacthal, chlorbenside, pentachlorophenol, and sulfallate, for example, have 
been shown to reduce Pgp-mediated Rho-123 efflux from special gill cells in the mussel 
Mytilus galloprovincialis (Cornwall et al., 1995; Galgani et al., 1996). Similarly, in 
mussels (M. galloprovincialis), exposure to Diesel-2 oil increased accumulation of the 
Pgp substrate, 3H-vincristine (VCR) threefold (Kurelec, 1995). On the opposite extreme, 
induction of Pgp has also been observed following exposure to environmental 
contaminants. Polycyclic aromatic hydrocarbons, including benzo[a]pyrene (BaP) and 3-
methylcholanthrene (3-MC) (Fardel et al., 1996), and the carcinogen 2-
acetylaminofluorene (AAF) (Chieli et al., 1995; Tateishi et al., 1999) increased 
expression of Pgp in rat hepatocytes. As a consequence, absorption and disposition of 
Pgp mediated xenobiotics may be altered by a variety of compounds in environmental 
mixtures, which inhibit or induce Pgp.  
In the aquatic environment, certain contaminants may have the potential to 
interact with the lipid membrane and/or Pgp transporter, leading to altered bioavailability 
and bioaccumulation of other pollutants and drugs from the environment. In the present 
studies, the pesticide dieldrin and surfactant linear alkylbenzene sulfonate (LAS) were 
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selected as model contaminants to investigate their effects on xenobiotic bioavailability 
and bioaccumulation because of their possible interactions with the lipid membrane 
and/or Pgp transporter, environmental relevance, and their frequent exposure to fish and 
other wildlife.  
Dieldrin is an extremely persistent and toxic organochlorine pesticide, which has 
been shown to readily bioaccumulate in fish, wildlife and humans (ASTDR 2002). It is 
found in all environmental media. Fish are at high risk of being exposed to dieldrin 
through the food chain and direct contact (Jorgenson, 2001). Studies have shown that 
dieldrin is a potent activator of human pregnane X receptor (PXR) (Coumoul et al., 2002; 
Lemaire et al., 2004), which is the master regulator for Pgp and CYP 3A4 expression 
(Veau et al., 2002; Matheny et al., 2004). In addition, chronic dieldrin treatment altered 
hepatic disposition of 14C-dieldrin and 3H-7, 12-dimethylbenz[a]anthracene (DMBA) 
(Gilroy et al., 1993 and 1996), and stimulated biliary excretion of 3H-DMBA and 14C-
BaP in rainbow trout (Donohoe et al., 1998; Barnhill et al., 2003). These results were 
evident without induction of xenobiotic metabolizing enzymes, suggesting that 
transporter interactions may be operative with these findings.      
Surfactants, common environmental pollutants and mixture components in 
aquatic systems (Ahel et al., 1993; Todorov et al., 2002), generally exhibit a low order of 
direct toxicity to aquatic organisms, however, several early studies suggest that 
surfactants may have an effect upon the bioavailability and disposition of 
environmentally relevant compounds in fish (Mann, 1962; Solon, et al., 1969; Pärt et al., 
1985). Contemporary studies on the involvement of ABC transporters in cancer 
multidrug resistance have shown that surfactants are able to inhibit Pgp’s contribution to 
this phenomenon (Kabanov et al., 2002).  Recently, surfactants used in drug formulations 
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have been shown to increase intestinal absorption and decreased the elimination of drugs 
through alteration of membrane permeability (Drori et al., 1995; Hendrich and Michalak, 
2003) and/or modulation of ABC transporters (Woodcock et al., 1992; Nerurkar et al., 
1996; Regev et al., 1999; Alqawi and Georges, 2003). Therefore, through these actions, it 
is of interest to determine if surfactants at environmentally relevant concentrations may 
influence bioavailability or bioaccumulation of other more hazardous xenobiotics present 
in environmental mixtures.  
The overall objective of these studies was to investigate the influence of the 
pesticide, dieldrin, and the widely used surfactant, linear alkylbenzene sulfonate (LAS) 
on xenobiotic bioavailability and bioaccumulation through the alteration of ABC 
transporters and/or membrane permeability. The first hypothesis examined in the in situ 
isolated perfused liver and in vivo in the catfish if the disposition and pharmacokinetics of 
the drug tetracycline may be altered by dieldrin through Pgp inhibition or induction. 
Tetracycline was chosen for its structural similarity to Rho-123, the prototypic Pgp 
substrate, its minimal metabolism in the body (Aronson, 1980) and its widespread use in 
humans and animals. The second hypothesis examined if C18 LAS at environmentally 
relevant concentrations may alter membrane permeability and/or the efflux activity of 
Pgp in the bile canniculi of the catfish liver and influence the in vivo dietary 
bioaccumulation of the pharmaceutical drug ivermectin (IVM) and pro-carcinogen 
benzo(a)pyrene (BaP) in catfish. The widely used veterinary pharmaceutical ivermectin 
and the PAH and environmental contaminant benzo[a]pyrene (BaP) were selected as 
model compounds based on their possible involvement with ABC transporters, 
environmental relevance and their otherwise limited bioaccumulation.  
 5
In order to address the above questions, the specific objectives of these studies are 
as follows: 
1. To characterize the effects of dieldrin and tetracycline on Pgp transport activity using 
isolated perfused liver preparations. 
2. To evaluate the effect of dieldrin on biliary excretion of 3H-tetracycline in the in situ 
isolated perfused livers. 
3. To examine the effects of chronic dieldrin pretreatment on the in vivo 
pharmacokinetics and disposition of 3H-tetracycline in catfish. 
4. To evaluate Pgp expression in association with alterations of pharmacokinetics and 
disposition of 3H-tetracycline in dieldrin pretreated catfish. 
5. To investigate the influence of C18 LAS at environmentally relevant concentrations on 
movement of the Pgp prototypic substrate Rhodamine-123 into bile in the in situ isolated 
perfused livers.   
6. To assess fluidity changes in the corresponding hepatic membranes and their 
relationship with inhibitory effects of LAS on movement of Rhodamine-123 into bile in 
the in situ isolated perfused livers. 
7. To investigate the effects of the C18 LAS surfactant at environmentally relevant levels 
on the in vivo bioavailability and bioaccumulation of 3H-IVM and 3H-BaP in catfish. 
The first chapter of this dissertation presents a literature review of the discovery, 
structure, action mechanisms and substrate specificity of ABC transporters Pgp and Mrp, 
a discussion of possible mechanisms that may modulate transport function or induce the 
overexpression of these ABC transporters, membrane permeability as well as relevant 
xenobiotics in these studies. The second chapter examines effects of dieldrin upon 
pharmacokinetics and disposition of tetracycline through interactions with Pgp in in situ 
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isolated perfused livers and in vivo catfish. The third chapter investigates the effect of 
C18 LAS on the function of Pgp and membrane permeability in the isolated perfused 
livers and the influence of LAS at environmentally relevant concentrations on the in vivo 
bioaccumulation and bioavailability of 3H-IVM and 3H-BaP. The fourth chapter presents 
an overall summary and general conclusions.   
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CHAPTER 1: LITERATURE REVIEW 
 
ABC TRANSPORTERS: PGP AND MRP 
 
Background: The Multidrug Resistance (MDR) 
The phenomenon of multidrug resistance (MDR) was first discovered in the early 
1970s. After a course of chemotherapy, tumor cells were found to exhibit reduced 
sensitivity to the administered drugs and a variety of other compounds. These cross-
resistant agents appeared to have no common chemical structure, pharmacological 
function or pathway of biotransformation (Kessel et al., 1968; Biedler et al., 1975). 
Subsequent studies have shown that this form of resistance can be attributed to an active, 
ATP-dependent efflux of various agents from inside the cell across the plasma membrane 
to the outside (Higgins et al., 1998; Dean et al., 2001).  P-glycoprotein (Pgp) was the first 
and best studied membrane transporter involved in this resistance phenotype in cancer 
cells (Juliano and Ling, 1976). The second major protein responsible for MDR is the 
multidrug resistance-related protein (Mrp). Pgp and Mrp both belong to the ABC (ATP 
binding cassette) protein superfamily, containing conserved sequences for ATP binding 
and hydrolysis (Doige and Ames, 1993; Higgins, 1992). Therefore, these proteins have 
been proposed to actively transport chemical agents across the plasma membrane using 
the energy released by ATP binding and hydrolysis (Doige and Ames, 1993).  
Although, the physiological role of Pgp and Mrp is unknown, it has been 
suggested that they are associated with an ancient-type cellular immune apparatus, 
providing resistance to endogenous and exogenous toxicants (Sarkadi et al., 1996). In 
addition to tumor cells, these proteins are located in intestine, liver, kidney, adrenal 
gland, placenta, testes and blood-brain barrier (Cordon-Cardo et al., 1989, Thiebaut et al., 
1987). The anatomical localization of Pgp and Mrp suggests that these MDR transporters 
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may play an important role in absorption, distribution, and excretion of endogenous and 
exogenous chemicals (Lin, 2003). 
MDR in Aquatic Organisms 
ABC transporters are members of a superfamily of transmembrane (TM) proteins. 
This family is one of the largest and most ancient protein families with representatives in 
all living organisms from prokaryotes to mammals (Higgins and Gottesman, 1992; 
Ambudkar et al., 1999).  Highly conserved MDR genes (encode Pgp) or Pgp-like proteins 
have been observed in different aquatic organisms including sponges, oysters, clams, 
worms and fish (Toomey and Epel, 1993; Waldmann et al., 1995; Minier et al., 1996; 
Kurelec et al., 1992; Kleinow et al., 2000). Studies with fish have shown a high sequence 
homology (Chan et al., 1992), a similar tissue distribution pattern (Kleinow et al., 2000), 
and transport function consistent with that demonstrated in mammals (Schramm et al., 
1995). Mrp-related genes or proteins have also been found in Atlantic killifish (Fundulus 
heteroclitus), dogfish shark (Squalus acanthias) and red mullet (Mullus barbatus) (Miller 
et al., 1998; Sauerborn et al., 2004; Miller, 2003). 
The MDR-like phenomenon occurring in aquatic organisms is referred to as 
multixenobiotic resistance (MXR). Pgp and Mrp in aquatic organisms may constitute a 
“first line of defense” to prevent absorption and facilitate elimination of endogenous and 
exogenous toxicants (Epel, 1998; Kurelec, 1995). This role in chemical defense may 
contribute to the observation that many aquatic species are able to survive and reproduce 
successfully in highly contaminated environments with multiple anthropogenic pollutants 




Structure and Mechanisms of Action 
The classification of ABC proteins is based on the sequence and organization of 
their conserved nucleotide binding domain(s) as well as the homology in the gene 
structure (Leslie et al., 2005). Typical ABC transporters contain a four-domain structure 
with two conserved nucleotide binding domains (NBDs) and two membrane spanning 
domains (MSDs) each consisting of six membrane spanning helices. In this structure, 
each MSD is followed by a NBD (MSD-NBD-MSD-NBD) (Fig. 1. B) (Loo and Clarke, 
1999). The 170 kDa Pgp (encoded by ABCB1 or MDR gene) is a typical ABC protein, 
whereas the 190 kDa Mrp1 and Mrp2 (encoded by ABCC gene) have an atypical 
structure with five domains. They contain a typical four domain structure, preceded by an 
extra NH2-proximal MSD domain composed of five membrane spanning helices (MSD-
MSD–NBD–MSD–NBD) (Fig. 1. A) (Bakos et al., 1996; Hipfner et al., 1997).   
NBDs, considered as the sites for ATP recognition, binding and hydrolysis, are 
located on the cytoplasm side of the membrane (Higgins et al., 1986).  For most ABC 
transporters, each NBD contains three highly conserved sequence motifs: the Walker A, 
the Walker B and the Signature C. The specific amino acid residues in either the Walker 
A or the Walker B are considered to be important for the ATP hydrolysis. Studies showed 
that changes in these residues would abolish the ATP hydrolysis of Pgp (Hrycyna et al., 
1999). The signature motif has been linked to the conduction of energy from ATP binding 
and hydrolysis to the transmembrane regions, leading to the conformation changes and 
the substrate translocation in the transmembrane regions (Hyde et al., 1990).  
MSDs contain the substrate binding sites. The structural divergence in these sites 
may result in differences in substrate specificities among ABC transporters (Chang, 
2003). Studies have shown that Pgp contains at least two different binding sites or one 
 14
large complex binding bucket (Boer et al., 1996; Pascaud et al., 1998; Ferte, 2000), which 
may interact in a positively cooperative fashion (Shapiro and Ling, 1997). Mutually 
stimulated transport has been observed in Pgp for transport of Rhodamine and 
progesterone (Shapiro and Ling, 1997; Shapiro, 1999).  
 
Figure 1.1 - Predicted secondary structures of ABC transporters for (A) Mrp1 and Mrp2 
and (B) P-glycoprotein. MSD, membrane spanning domain; NBD, nucleotide binding 
domain; CL, cytoplasmic loop (Modified from Leslie et al., 2005). 
 
Classic membrane transporters usually move the substrate from the aqueous 
cytosol to the extracellular aqueous space via an aqueous pore. This pump model is not 
supported by Pgp mediated transport across the plasma membrane. It is clear that Pgp 
takes hydrophobic substrates from the lipid phase within the inner leaflet of the bilayer 
membrane (Stein et al., 1994). The substrate must interact with the lipid phase of the 
bilayer membrane before reaching Pgp. Based on these findings, a hydrophobic vacuum-
cleaner model has been proposed for Pgp transport in which chemicals are extracted 
directly from the membrane to the extracellular medium (Higgins and Gottesman, 1992). 
But this model can not adequately explain the means by which Pgp specifically binds to 
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different substrates (Liu and Sharon, 1996). Thus, another hypothesis has been proposed 
that Pgp acts as a flippase, moving chemicals against an intramembrane concentration 
gradient from the inner leaflet to the outer of the plasma membrane where they can 
diffuse to the aqueous medium (Gottesman and Pastan, 1993). This model provides some 
basis for understanding the specificity of Pgp by considering compound interactions with 
lipid membranes. 
Substrate Specification 
One unique characteristic of Pgp and Mrp is their broad substrate specificity.  The 
therapeutic drugs transported by Pgp include many anti-cancer agents (Gottesman and 
Pastan, 1993), HIV protease inhibitors (Lee et al., 1987), immunosuppressants (Meador 
et al., 1987), antibiotics (Horio et al., 1989) and steroids (Ueda et al., 1992).  Besides 
drugs, a number of environmental contaminants have been identified as substrates of Pgp, 
including carcinogen 2-acetylaminofluorene (AAF), the hydrophobic xenobiotics Aroclor 
1254, DDT, DDD, and DDE, and the hydrophobic pesticides dacthal, chlorbenside, 
sulfallate and pentachlorophenol (Kurelec and Pivcevic, 1991; Cornwall et al., 1995; 
Galgani et al., 1996; Kurelec et al., 1996). The most common properties shared by these 
compounds are moderately hydrophobic or amphiphilic, low molecular weight, positively 
charged or neutral compounds with a planar structure (Gottesman and Pastan, 1993; 
Kusuhara et al., 1998). The prototypic substrates of Pgp, such as Vinca alkaloids, 
anthracyclines, epiodophyllotoxins, rhodamine dyes (Argast and Beck, 1984; Sharom, 
1997) and doxorubicin (Mealey et al., 2002), are amphiphilic compounds with a four-
ringed structure. This structure and physical properties may enhance partitioning into the 
cell membrane and the active interaction with Pgp (Bain et al., 1997). 
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Mrp mainly effluxes conjugates of organic anions with glutathione, glucuronide 
and sulfate (Konig et al., 1999; Leslie et al., 2001). Pgp primarily transports drugs to 
which it confers resistance, while Mrp acts cooperatively with conjugate enzymes such as 
the glutathione S-transferases and UDP-glucronosyltransferases to confer resistance to 
drugs (Depeille et al., 2004; Smitherman et al., 2004). The conjugates of environmental 
toxins and drugs identified as Mrp substrates include aflatoxin B, metolachlor, 
chelerythrine, arsenic and vincristine (Leslie et al., 2004; Loe et al., 1997; Lou et al., 
2003).  The conjugated metabolites are generally thought to be less reactive and toxic as 
compared to unconjugated toxins. However, Mrp efflux prevents cellular accumulation of 
these conjugated chemicals, which may result in reformation of the active parent 
compounds, or direct inhibition of conjugation enzymes and other important enzymes for 
the cell viability (Leslie et al., 2005).  In humans, the lack of Mrp2 transport function 
may lead to Dubin–Johnson syndrome, associated with impaired biliary excretion of 
bilirubin glucuronides and other anionic conjugates (Kajihara et al., 1998; Toh et al., 
1999).   
MDR/MXR Inhibition 
Broad substrate specificity provides an advantage for Pgp to deal with a wide 
range of potentially toxic agents. However, Pgp transport may be inhibited when too 
many substrates or noncompetitive inhibitors are present. Pgp inhibition may result in an 
increase in the systemic bioavailability and bioaccumulation as well as changes in tissue 
distribution. 
Pgp is thought to have more than one substrate binding site and two ATP binding 
domains, which interact cooperatively as a functional unit (Lin, 2003).  Inhibitors may 
interfere with Pgp at different sites. Verapamil has been shown to inhibit transport 
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function of Pgp in a substrate competitive manner (Ford, 1996). Some modulators are not 
in fact substrates of Pgp but may inhibit Pgp transport indirectly. Certain 
organophosphorus and organochlorine pesticides which have high affinity to bind Pgp, 
but are not transported can disrupt the Pgp activity (Bain and Leblanc, 1996). Vanadate 
binds with the ATP-binding sites of Pgp without blocking substrate binding, while 
cyclosporine A inhibits Pgp activity by interfering with both substrate recognition and 
ATP hydrolysis (Ramachandra et al., 1998; Tamai et al., 1991).   
 Recent studies indicated that Pgp transport activity is particularly sensitive to 
changes in the physicochemical state of membrane lipids, especially those surrounding 
Pgp (Callaghan et al., 1997; Doige et al., 1993). ATPase activity of Pgp, directly linked 
to Pgp transport activity, could be changed by addition of membrane fluidizers such as 
ethanol and detergents (Doige et al., 1993; Regev et al., 1999). The modulation of Pgp 
ATPase activity here may result from conformation changes induced in the 
transmembrane region and transmitted to ATP binding domains (Ferté, 2000). 
Furthermore, some evidence suggests that ATP binding sites, which were usually 
depicted as extending to the cytosol, could be physically close to the membrane surface. 
Alterations of the membrane state may directly affect ATPase activity of Pgp (Liu and 
Sharom, 1998).   
Environmental contaminants have been found to inhibit Pgp activity in marine 
and freshwater concentrates, sediment, soil, industrial or household waste extracts, 
hospital waste, Diesel-2 oil and algal extract (Smital et al., 2004). These chemicals 
classified as chemosensitizers may increase bioaccumulation of environmental toxicants 
and toxicity sensitivity in cells and organisms through inhibition of Pgp transport 
(Kurelec, 1995).  Studies with mussels (M. galloprovincialis) showed that exposure to 
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Diesel-2 oil resulted in accumulation of 3H-vincristine (VCR) threefold greater than upon 
exposure to VCR alone (Kurelec and Pivcevic, 1991).   Likewise, mussel embryos (M. 
edulis) which were exposed to vinblastine, mitomycin-C, cytocholasin D, chloroquine, or 
colchicine showed an increase in number and severity of deformities after verapamil 
addition (McFadzen et al., 1999).  
MDR/MXR Induction 
Exposure to drugs or contaminants frequently leads to the acquisition of 
xenobiotic resistance mechanisms, which may act as a generalized response to cellular 
stress (Bard, 2000).  A wide range of chemicals have been observed to induce MDR1 
mRNA and Pgp, regardless if they are Pgp substrates or not. These agents include 
anticancer drugs (Chaundhary and Roninson, 1993), DNA-damaging agents ( Fardel et al., 
1998), tumor necrosis factor alpha (TNF-α) (Hirsch-Ernst et al., 1998) as well as 
environmental contaminants such as 2-acetylaminofluorene, aflatoxin B1, 
Benzo[a]pyrene and 3-methylcholanthrene (3-MC) (Fairchild et al., 1987; Chin et al., 
1990; Gant et al., 1991; Doi et al., 2000).     
Regulation of Pgp expression in response to inducers has been extensively studied 
in vitro and in vivo (Moore et al., 2000; Staudinger et al., 2001). Most evidence points to 
an orphan nuclear receptor, pregnane X receptor (PXR), which plays a central role in the 
regulation of  expression of Pgp as well as CYP2 and CYP3A (Kretschmer and Baldwin, 
2005; Handschin and Meyer, 2005). The PXR was named after a class of steroid, 
pregnane, which can activate this receptor. Besides pregnane, a broad range of 
structurally unrelated compounds, including drugs rifamipicin, dexamethasone and 
heperofin, as well as environmental contaminants dieldrin, DDT, DDE and endosulfan 
(Lemaire et al., 2004; Coumoul et al., 2002; Wyde et al., 2003),  activate PXR. PXR is 
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expressed in the liver, intestine and brain (Harmsen et al., 2007). In response to 
activation, PXR forms a heterometer with the retinoid X receptor (RXR), which 
subsequently binds to the promoter region of the target genes such as MDR1, Mrp and 
CYP3A genes, and stimulates transcription (Timsit and Negishi, 2007).   
Although PXR plays a key role in Pgp induction, other mechanisms such as gene 
amplification, transcriptional control and post translation modifications, are all possibly 
involved in increased expression of Pgp in response to inducers (Bard, 2000; Lin, 2003). 
MDR1 gene amplification has been observed in some resistant cell lines (Roninson et al., 
1986), but is not required for increased expression of Pgp (Shen et al., 1986).  Post-
transcriptional controls, such as phosphorylation state and increased mRNA 
stability/decreased mRNA half-life, are also important for MDR1 expression. Studies 
have demonstrated that phosphorylation of serines and threonines on Pgp is associated 
with elevated drug resistance in mammalian cell lines (Ratnasinghe et al., 1998). 
MEMBRANE PERMEABILITY 
Membrane permeability is the ability of compounds to move across the biological 
membrane. Permeation across the cell membranes takes place by three main mechanisms: 
passive diffusion, passive transport (channels or carriers) and active transport (carriers). 
Diffusion across the cell membrane constitutes the most important mechanism, by which 
xenobiotics cross the membrane (Malkia et al., 2004). 
The extent of membrane permeability is largely governed by the physiochemical 
properties of xenobiotics. Lipophilicity is a crucial factor for membrane permeability of 
chemicals (Ayrton and Morgan, 2001). Other molecular characteristics such as molecular 
size, charge, volume, hydrogen-bonding capacity may alter the diffusion rate across the 
biological membrane (Hilgers et al., 1990, Camenisch et al., 1996).  On the other hand, 
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diffusion of xenobiotics is also influenced by membrane lipid composition, structural 
integrity, membrane thickness and cytosolic characteristics (Fine et al., 2001; Kleinow, 
2006).   
Membrane Permeability and MDR 
Membrane permeability and Pgp transport function are interdependent and for all 
practical purposes inseparable. The functional vectorial transport of substrates in an 
efflux fashion by Pgp has been clearly shown to be dependent on the passive permeability 
of the membrane to the transported substrate in the opposite direction (Eytan et al., 1996 
and 1997). Compounds considered to be non-transported modulators of Pgp exhibit 
greater permeability and inward diffusability (Scala et al., 1997; Mülder et al., 1995). For 
these compounds, if efflux transported by Pgp, movement may be unrecognizable due to 
the membrane’s inability to maintain the transporter generated gradient and will allow 
concentration dependent compound back-diffusion (Barnes et al., 1996; Fert’e, 2000). 
Rho-123, a prototypic substrate of Pgp, on the other hand, demonstrates restricted 
membrane movement and vectorial efflux transport is evident (Speelmans et al., 1994; 
James et al., 1977). Ccompetitive Pgp modulators like verapamil are more lipophilic and 
diffusible than other substrates effluxed by Pgp, allowing diffusion back into the cell 
(Sharom, 1997). Therefore, the degree of membrane permeability for a compound is a 
determinant of net transport. 
XENOBIOTICS: ENVIRONMENTAL RELEVANCE AND 
INTERACTIONS WITH ABC TRANSPORTERS 
 
Dieldrin 
Dieldrin is a chlorinated cyclodiene compound belonging to a class of synthetic 
organochlorine pesticides (Fig. 1.2) (Hassell, 1990). It was first synthesized in 1946 and 
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distributed commercially as an alternative to DDT (Dichloro-Diphenyl-Trichloroethane) 
in 1950. Dieldrin was broadly used as an insecticide around the world in the middle of 
1970s, mainly for the control of tsetse flies and soil pests and for the treatment of seeds. 
Dieldrin was listed as one of the 12 most persistent bioaccumulative and toxic (PBT) 
pollutants by the US Environmental Protection Agency (US EPA, 2001) and one of the 
top 20 hazardous substances to humans (ATSDR, 2005). Due to its extreme persistence 
and toxicity, US EPA finally banned the use of this insecticide in 1987. However, it is 
still used in a few developing countries (Suwalsky et al., 2002). 
Even though banned from use for decades in most of the world, significant levels 
of dieldrin continued to be found in soil, water, and biota because of its low volatility and 
chemical stability (ASTDR, 1987). An epidemiological study conducted in Taiwan 
revealed dieldrin at concentrations of 0.12–5.8 μg/kg sediment (dry weight) in the 
impacted river (Doong et al., 2002).  In Japan, low levels of dieldrin and other pesticide 
residues were observed in 32% of domestic agricultural products and 51% of imported 
products (Akiyama et al., 2002). In India, high levels of dieldrin (> 1 μg/g) in vegetables 
were reported (Kannan et al., 1997), suggesting higher contamination levels in 
developing countries. Animals and humans may be exposed to this compound through 
the food chain and direct contact (ASTDR, 2002). Recently, the high levels of dieldrin 
have been found in farmed salmon fish worldwide (Hites et al., 2004). An investigation 
on human exposure to dieldrin demonstrated that farmers in Iowa have significantly 
higher serum dieldrin concentrations. In this case, dietary dieldrin is a major route for 
human exposure (Brock et al., 1998).          
Effects of organochlorine compounds on Pgp transport have been investigated, 
but the results were equivocal. Organochlorine compounds including DDT, DDD and 
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DDE, have been shown to reduce the efflux transport of the prototypic Pgp substrate 
Rhodamine B from the gills in the marine mussel M. galloprovinvialis (Galgani et al., 
1996). However, DDT, DDE and dieldrin had no effect on the intracellular accumulation 
of another Pgp substrate doxorubicin in the murinne melanoma cell lines infected with 
human MDR1 gene (Bain and Leblanc, 1996). Inconsistency was also observed with in 
vitro studies in gill cells of different mussel species. DDT, DDD, DDE, and 
polychlorinated biphenyl--Aroclor 1254 all inhibited the efflux of Rhodamine dye from 
the gill cells in one species of mussel (Mytilus galloprovincialis) (Galgani et al., 1996), 
but showed no effect on Pgp transport activity in another species (Mytilus californianus) 
(Cornwall et al., 1995).  The reasons for this inconsistency are still not clear, and may 
result from tissue, dosage, species, or other experimental differences.   
 
Figure 1.2 - Chemical structure of dieldrin (Modified from Hassell, 1990).  
Previous studies demonstrated that chronic dieldrin treatment altered hepatic 
disposition of 14C-dieldrin and 3H-7, 12-dimethylbenz[a]anthracene (DMBA) (Gilroy et 
al., 1993 and 1996) and increased biliary excretion of 3H-DMBA and 14C-B(a)P in 
rainbow trout (Donohoe et al., 1998; Barnhill et al., 2003). These results were evident 
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without induction of xenobiotic metabolizing enzymes, suggesting that another 
mechanism, such as transport actions, may be operative with these findings. In addition, 
in vivo studies have shown increased expression of Pgp following exposure of another 
organochlorine compound DDE in the gill tissues of the mussel Mytilus californianus 
(Eufemia and Epel, 2000). These findings suggest that dieldrin may induce Pgp 
expression.  
Furthermore, dieldrin and other organochlorine compounds, such as DDT, DDE 
and endosulfan have been shown to interact with pregnane X receptor (PXR), which 
plays a central role in the regulation of  induction of CYP2 and CYP3A as well as Pgp 
(Kretschmer and Baldwin, 2005; Handschin and Meyer, 2005). Exposure to these 
compounds has resulted in induction of CYP3A and CYP2B in mammary cells (Lemaire 
et al., 2004; Coumoul et al., 2002; Wyde et al., 2003). These findings suggest that 
dieldrin may have a potential to induce Pgp expression through activation of PXR.  
 In summary, dieldrin as one of the persistent organic contaminants may have 
potential to inhibit or induce Pgp.   
Tetracycline 
The tetracycline antibiotics, a group of four-ringed amphoteric compounds (Fig. 
1.3), are commonly used as a broad-spectrum antimicrobial agent to inhibit the growth of 
bacteria, protozoa and intracellular organisms in human and veterinary medicine. In 
1970, oxytetracycline was approved by the US FDA for use to treat bacterial infections in 
salmons and catfish consumed by humans (Plakas et al., 1998).  Tetracycline may be 
administered through an intravenous, intramuscular, or oral pathway. Once absorbed, 
tetracycline is widely distributed throughout the body and then accumulated in the liver 
and kidneys. Tetracycline is not significantly metabolized in the body and mainly 
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eliminated as parent compounds through feces and urine (Aronson, 1980). Enterohepatic 
circulation may occur with tetracycline (Kunin and Finland 1961). 
Bacterial resistance to antibiotics often occurs during the clinical treatment. It 
involves two major mechanisms: the bacterial cell wall permeability barrier and the 
active multidrug transport proteins (De Rossi et al., 2006). The active transport proteins 
found in bacteria exhibit a high degree of sequence homology with Pgp (Chen et al., 
1986; Neyfakh 1997) and similar characteristics to the multidrug resistance system in 
mammalian cells (Neyfakh et al., 1991). Studies performed in bacteria revealed that 
MDR gene transfection resulted in reduced intracellular accumulation of tetracycline 
(Levy, 1992; George et al., 1996; Chollet et al., 2004). In addition, cyclosporine A and 
verapamil, the competitive inhibitors of Pgp, completely reversed tetracycline resistance 
and increased accumulation of tetracycline in the human leukemic cells expressing 
MDR1 gene (Kavallaris et al., 1993). A tetracycline derivative doxycycline has also been 
shown to potentially inhibit transport activity of Pgp and induce overexpression of Pgp in 
MCF-7 breast carcinoma cells (Kavallaris et al., 1993).     
 
Figure 1.3 – Chemical structure of tetracycline. 
 
Surfactants 
Surfactants (surface-active agents) are a diverse group of chemicals designed for 
cleaning and/or solubilization. They are usually amphiphilic organic compounds 
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containing both hydrophobic parts (their nonpolar tails) and hydrophilic parts (their polar 
heads). Therefore, they are readily soluble in both organic solvents and water.  These 
compounds are widely used for domestic and industrial applications, such as household 
cleaning, personal care products, paints, and paper industries. These agents are also 
employed as adjuvants in pesticide and pharmaceutical formulations and as dispersants in 
the remediation of soil contaminated by heavy metals and PAHs. (Burchfield et al., 1994, 
Baran Jr. et al., 1998; Cowell et al., 2000). Due to their widespread use, the world 
consumption of synthetic surfactants reached up to 7.2 million tons annually (Di Corcia, 
1998).   
Linear Alkylbenzene Sulfonates (LAS) 
 
Figure 1.4 - Chemical structure of linear alkylbenzene sulfonate (LAS) where x plus y 
equals 7 to 11 depending on the length of the alkyl chain (Adapted from Trehy et al., 
1996). 
Linear alkylbenzene sulfonate (LAS), the most popular synthetic anionic 
surfactant, constitutes more than 40% of total surfactants in the detergent industry (Verge 
et al., 2001).  The basic structure of LAS is a benzene ring connected to an alkyl chain 
with different lengths ranging from 9 to 13 carbon units (the nonpolar tail) and a sodium 
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sulfate group (the polar head) (Fig. 1.4) (Trehy et al., 1996). Commercial products of 
LAS are very complex mixtures consisting of different homologues.  
After use and disposal, LAS may directly reach surface water, sediment and soil, 
or be discharged as residuals from sewage treatment plants (Jensen, 1999). LAS are 
readily biodegradable under aerobic conditions (Perales et al., 1999). However, due to the 
widespread use and high consumption, various levels of LAS have been detected in the 
aquatic environments. LAS has been found in sewage effluents and in surface waters in 
the UK (1090 and 416 μg/l) (Holt et al., 1998; Fox et al., 2000) as well as in the effluents 
of wastewater treatment plants in the US (4 to 94 μg /l) (Trehy et al., 1996). LAS has also 
been reported at concentrations of 20 to 1000 μg/l in outlets to estuaries and near-shore 
marine waters in the North Sea (Berna et al., 1991; Stalmans et al., 1991), and 0.1 to 2.8 
μg/l in Mississippi River water (Tabor and Barber, 1996). LAS levels in sediments have 
been reported to be much higher than in water due to much lower degradation rates under 
anaerobic conditions. 49-129 µM LAS/kg dry weight (dw) is reported in sediments in the 
Tsurumi River, Japan (International Program on Chemical Safety, 1996), and 0.11-0.30 
µM LAS/kg dw in the German Bight of the North Sea (Berna et al., 1991; Stalmans et al., 
1991). 
Studies in fish revealed that LAS is mainly absorbed through gills, rapidly 
distributed throughout the body, highly concentrated in gills, blood, hepatopancreas and 
kidneys, and primarily eliminated through bile (Kikuchi et al., 1978). In general, 
surfactants cause disruptions of the biological membrane and denaturation of membrane 
proteins (Swisher, 1987; Schwunger and Bartnik, 1980).  Exposure to high concentrations 
of LAS results in inhibition of mobility, reproduction and growth, and even death of fish 
(Verge et al., 2001; Utsunomiya et al., 1997; Hofer et al., 1995; Singh et al., 2002).  The 
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No Observed Effect Concentration (NOEC) and the Predicted No-Effect (PNEC) of LAS 
for freshwater were 200 and 360 µg/l, respectively. As the thresholds of the defined acute 
and chronic toxicity for LAS in aquatic organisms are much higher than the measured 
environmental levels, the direct toxic effects of LAS are assumed to be low in the 
environment (Ying GG, 2005; Scott and Jones, 2000). As a common environmental 
pollutant, LAS often exists in mixtures with other contaminants. Mixtures of toxicants 
containing LAS may result in additive or even synergistic effects on fish and other 
organisms (Lewis, 1992). Several early studies have shown that LAS exposure resulted in 
enhanced uptake and altered disposition of other compounds such as phenol (Mann, 
1962), pesticide parathion (Solon et al., 1969) and metals (Pärt et al., 1985, Calamari and 
Marchetti, 1973). These findings are linked to alterations of membrane permeability by 
surfactants.  
Surfactants and Multidrug Resistance 
Surfactants have been extensively employed as excipients in the pharmaceutical 
formulations to facilitate drug absorption (Rege et al., 2002).  Initially, they were 
considered as physiologically insert compounds for enhancing drug solubility.  However, 
recent studies suggested that these compounds may insert into the lipid membrane to 
varying degrees, and increase membrane fluidity (Sinicrope et al., 1992; Woodcock et al., 
1992; Swenson et al, 1994), disrupt tight junctions between the epithelial cells (Aungst 
2000; Anderberg et al., 1992), and interact with metabolic enzymes (Mountfield et al., 
2000). Moreover, they have been shown to inhibit the efflux activity of ABC transporters 
Pgp and Mrps (Bobrowska-Hagerstrand et al., 2003; Ellis et al., 1996; Orlowski et al., 
1998; Strugala et al., 2000). The modulation of Pgp and related ABC transporters is of 
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particular interest as their critical role in xenobiotic accumulation and disposition in the 
body. 
Surfactants including Cremophor EI, Solutol HS15, Triton X-100, Nonidet P-40 
and Pluronic block copolymers, have been observed to increase accumulation and 
cytotoxicity of antineoplastic agents in tumor cells overexpressing Pgp and in vivo mice 
carrying with MDR tumors (Batrakova et al., 1996; Webster et al., 1993; Dudeja et al., 
1995; Buckingham et al., 1995; Zordan-Nudo et al., 1993). Recently, pluronic polymer 
bound doxorubicin has been developed and undergone phase I clinical trials to treat MDR 
tumors (Danson et al., 2004).  Surfactant-induced MDR inhibition not only occurred in 
MDR tumor cells, but also in normal tissues such as in liver (Ellis et al., 1996), intestine 
(Strugala et al., 2000) and blood brain barrier (Miller et al., 1997).    
The mechanism by which Pgp transport is inhibited by surfactants has been 
investigated.  Tween 80 and nonylphenol ethoxylates (NPEs) have been shown to inhibit 
Pgp transport by blocking the substrate binding to Pgp (Yamazaki et al., 2000; Friche et 
al., 1990; Doo et al., 2005). Batrakova discovered that surfactant Pluronic P85 was able 
to permeate the membrane of mitochondria, disrupt oxidative phosphorylation and lead to 
ATP depletion in the cell (Batrakova et al., 2001). Krylova and Pohl demonstrated that 
Puronic L61-induced ionic flux in the plasma membrane could result in compensatory 
ATP consumption by Na+-K+ ATPase and decreased cellular ATP levels (Krylova and 
Pohl, 2004). Studies with lipids and detergents indicated that perturbation of the 
membrane environment may alter Pgp transport function (Ferté, 2000; Doige et al., 
1993). These agents may change lipid mobility and structure in the plasma membrane, 
and consequently affect conformational changes of membrane bound protein Pgp (Rege 
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et al., 2002; Regev et al., 1999), which may be associated with Pgp’s ATPase activity (Lu 
et al, 2001). 
Likewise, surfactants may modulate Mrp and other membrane enzymes since they 
have potential to interfere with Pgp through membrane perturbation. Studies have shown 
that surfactant pluronic copolymer has inhibitory effects on Mrp transport (Miller et al., 
1999). Activities of membrane enzymes such as CYP3A and glutathione-S-transferase 
(GST) system were also decreased in the presence of surfactants (Johnson et al., 2002; 
Batrakova et al., 2004).  
   In addition, substrates of Pgp and Mrp are lipophilic or amphiphlic, which enter 
the cell via passive diffusions through the plasma membrane. The cellular accumulation 
of these compounds in MDR cells relies on membrane permeation properties as well as 
on the handling by the ABC transporters (Ferté, 2000). Surfactants, as amphipathetic 
molecules, whose structures imitate that of endogenous glycerophospholipids, are able to 
insert themselves between lipophilic tails of membrane bilayers, resulting in disorder of 
the lipid-packing arrangement of membranes. The net result is that the membrane 
becomes fluidized, facilitating the passive diffusion of compounds across the membrane 
(Lo, 2003), and thereby increasing membrane permeability and cellular accumulation 
(Drori et al., 1995; Hendrich and Michalak, 2003).  
Surfactants are common environmental pollutants and mixture components in 
aquatic systems. Therefore, it is of interest to determine if surfactants at environmentally 
relevant concentrations may influence bioavailability or bioaccumulation of other more 





Ivermectin (IVM) (22, 23-dihydroavermectin B1a + B1b) are the semi-synthetic 
derivatives from Streptomyces avermilities, consisting of a disaccharide linked to a 
macrocyclic lactone (Fig. 1.5) (Roberts and Hutson, 1999). It is a broad-spectrum 
antiparaside extensively used in veterinary and human medicine. In United States, IVM is 
approved for use in swine, cattle, sheep, goats, bison, reindeer, and horse. Recently, it has 
been applied to treat the sea lice in salmon (Stone et al., 2000). IVM primarily acts on the 
nervous system of parasites. It binds to glutamate-gated chloride channels and GABA (c-
amino butyric acid)-gated chloride channels, increases chloride influx, and results in 
hyperpolarization in nerves and muscle cells (Martin 1997). This disrupts neural signal 
transmission and paralyzes neuro-muscular junctions in organisms ultimately leading to 
death (Mellin et al., 1983).    
 
 
Figure 1.5 - Chemical structure of ivermectin (IVM) (Adapted from Roberts and Hutson, 
1999).   
At therapeutic doses, IVM does not affect mammals since glutamate and GABA 
synapses are located in the central nervous system (CNS), which is largely protected from 
the blood-brain barrier (Campbell et al., 1983). However, some dog species, most notably 
the collie, exhibit signs of CNS toxicity at IVM doses much lower than the normal 
therapeutic dose. The cause of CNS toxicity in susceptible dog species has been linked to 
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a mutation in a MDR1 gene (Mealy et al. 2001). High expression of Pgp in the blood 
brain barrier may protect the brain tissues from the penetration of IVM and its 
neurotoxicity (Schinkel et al., 1994). Several studies demonstrated that IVM interferes 
with Pgp as a substrate (Alvinerie et al., 1999; Ballent et al., 2006). Pgp modulators 
including verapamil, loperamide, PSC833 and itraconazole, have been shown to increase 
its IVM plasma and tissue concentrations after co-administration (Alvinerie et al., 1999; 
Lifschitz et al., 2004; Ballent et al., 2006). On the other hand, multidrug resistance in 
tumor cells has been reversed by IVM (Korystov et al., 2004).  All these findings 
suggested that Pgp plays a critical role in absorption, dispositions and bioavailability of 
IVM. 
Since its action mode is not limited to parasites, IVM may affect other organisms 
in the environment. In fish studies, it has been reported that IVMs were distributed 
extensively to the brain (Høy et al., 1990), indicating that fish have poorly developed 
blood brain barrier as compared to mammals and may be susceptible to IVM toxicity. 
IVM has also been shown to produce adverse effects on reproduction, biological function 
and survival of non-target aquatic and terrestrial organisms (Halley et al., 1993; Steel and 
Wardhaugh, 2002).          
 As a widely used veterinary drug, IVM may enter environmental waterbodies and 
fish through aquaculture practices, runoff /leaching from concentrated on-ground fecal 
material and municipal sources (Daughton and Ternes, 1999). Following administration, 
IVM is excreted mainly as a parent compound or active metabolites through faeces 
(McKellar and Benchaoui, 1996; Lumaret and Errouissi, 2002). The physicochemical 
properties of IVM are low water solubility, high molecular weight and high Kow 
(McKellar, 1997). Therefore, once discharged in the environment, it is readily absorbed 
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by organic matter, soil, sediment particles and fish. It may be rapidly photodegraded in 
water to less bioactive compounds by oxidative mechanisms (Halley et al. 1993). 
However, due to its high volume and frequent use, IVM is of concern for its 
environmental toxic effects and potential risks to human health through the food chain 
(Tisler et al., 2006).   
Benzo[a]pyrene 
Benzo[a]pyrene (BaP) is a ubiquitous procarcinogen, belonging to the family of 
the polycyclic aromatic hydrocarbons (PAHs). BaP and other PAHs occur as a byproduct 
of incomplete fossil fuel combustion such as in coke ovens, automobile exhaust, cigarette 
smoke, and charcoal grilling of food. Spills and accidents during the production and the 
transport of oil constitute another major source of BaP in the environment (ASTDR, 
1990). PAHs are frequently found in impacted aquatic environments, especially in 
contaminated sediments (EPA, 1991).  In a designated superfund site of New Bedford 
Harbor, USA, concentrations of PAHs have been reported to up to 170 μg/g dry weight in 
sediments (Pruell et al., 1990).                   
 Dietary BaP is an important route of exposure for aquatic species and humans as 
a consequence of movement of BaP and its metabolites along the food chain (Kleinow et 
al., 1998; Hattemer-Frey and Travis, 1991). Human exposure to BaP through the food 
chain has been shown to account for about 97% of the total daily intake (Hattemer-Frey 
and Travis, 1991). Fish inhabiting polluted waters containing PAH are likely to be 
exposed in the diet to PAHs and their metabolites in the food item (e.g. smaller fish or 
plants) (James et al., 2001). High concentrations of BaP in fish food products have been 
detected over the past decades (Loutfy et al., 2007).    
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BaP is a moderately lipophilic neutral compound. It is readily absorbed by aquatic 
animals from the gastrointestinal tract (Varanasi et al., 1989) and rapidly distributed to 
well-perfused organs in the body (Tyler et al., 1981).   BaP is primarily eliminated as 
water-soluble metabolites through hepatobiliary excretion and feces. Biotransformation 
of BaP can occur in two main phases. The phase I reaction involves interactions with 
mixed-function oxidases, especially the cytochrome P450s, and formations of diol-
epoxides, including B(a)P-7,8-dihydrodiol-9,10-oxide (BPDE), the major carcinogenic 
metabolite. In phase II reactions, various polar moieties such as glutathione (GSH), 
sulfate and glucuronic acids are conjugated to the phase I intermediate metabolites (Di 
Giulio et al., 1995; Leonard et al., 2001). As a result, only minor parent BaPs remain in 
body tissues (Di Giulio et al., 1995). The liver is regarded as the major site of metabolism 
for BaP, although the significant metabolism may occur in gastrointestinal tract, skin and 
lung (Perera, 1981).   
BaP is carcinogenic, mutagenic, teratogenic, and cytotoxic to various cells and 
organisms (Conney et al., 1994 ; Miller and Ramos, 2001). BPDE, the major reactive 
metabolite of BaP, is able to interact covalently with biological macromolecules (e.g., 
DNA, proteins) and form adducts (Hall and Grover 1990; Varanasi et al, 1989). 
Alternatively, BaP’s ultimate carcinogenic metabolite (BPDE) may be detoxified by GSH 
conjugation, which is catalyzed by glutathione S-transferase (Robertson et al., 1986).  
Previous studies suggest that BaP itself is probably not a substrate of Pgp 
(Schuetz et al., 1998). However, BPDE conjugates have been shown to be actively 
transported across the canalicular plasma membrane and intestinal Caco-2 cells (Buesen 
et al., 2003; Srivastava et al., 1998).  The accumulation of BPDE and its GSH conjugates 
is enhanced by reduction of MRP2 transporter function (Srivastava et al., 2002), 
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suggesting that MRP2 may play an important role in elimination of conjugated BaP 
metabolites. Therefore, in addition to GSH conjugation, the efflux of the conjugates of 
BPDE is essential for the cellular protection against BPDE-induced toxicity.   
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CHAPTER 2: EFFECTS OF DIELDRIN ON THE 
PHARMACOKINETICS AND DISPOSITION OF TETRACYCLINE 
IN IN SITU ISOLATED LIVER PREPARATIONS AND IN VIVO 




P-glycoprotein (Pgp) is an ATP-dependent efflux membrane protein belonging to 
the ATP-binding cassette (ABC) transporter superfamily, which plays a pivotal role in 
absorption, disposition and excretion of various drugs (Juliano et al., 1976; Ambudkar et 
al., 1999). It is found in a variety of tissues, including the luminal face of intestine and 
brain capillaries, and the apical membrane of liver and kidneys (Aryton and Morgan, 
2000). Its location in organs of absorption, the blood-brain interface and elimination 
suggests Pgp plays a role in the barrier function, tissues distribution and excretion of 
drugs (Wacher et al., 2001; Frohlich et al., 2004). Pgp transports various therapeutic 
drugs (Lin, 2003), certain food constituents (Balayssac et al., 2005), as well as a variety 
of contaminants (Galgani et al., 1996; Toomey et al., 1996; Bard, 2000; Leslie et al., 
2005). 
Numerous environmental xenobiotics have been shown to increase accumulation 
of Pgp substrates via inhibition of Pgp transport activity either as substrates or as 
noncompetitive inhibitors. Four hydrophobic pesticides including dacthal, chlorbenside, 
pentachlorophenol, and sulfallate have been shown to reduce Pgp-mediated Rho-123   
efflux from special gill cells in the mussel Mytilus galloprovincialis (Cornwall et al., 
1995; Galgani et al., 1996). Likewise, in mussels (M. galloprovincialis), exposure to 
Diesel-2 oil increased accumulation of the Pgp substrate, [3H]-vincristine (VCR) 
threefold (Kurelec, 1995). Induction of Pgp has been observed following exposure to 
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environmental contaminants. Polycyclic aromatic hydrocarbons, including 
benzo[a]pyrene (BaP) and 3-methylcholanthrene (3-MC) (Fardel et al., 1996), and the 
carcinogen 2-acetylaminofluorene (AAF) (Chieli et al., 1995; Tateishi et al., 1999) 
increased expression of Pgp in rat hepatocytes. Similarly, in vivo studies have shown 
induction of Pgp in intestine following exposure to the xenobiotic β-naphthoflavone 
(BNF) in catfish (Kleinow et al., 2000) and rat and human (Lown et al., 1996). As a 
result, pharmacokinetics, efficacy and bioavailability of drugs by which disposition is 
mediated by Pgp may be altered by environmental compounds, which inhibit or induce 
Pgp.  
Drug to drug interactions due to inhibition or induction of Pgp are widely 
recognized to be of clinical concern in that they may lead to altered pharmacokinetics, 
efficacy and bioavailability of Pgp transported drugs (Yu, 1999; Balayssac et al., 2005). 
The most overwhelming evidence of this phenomenon in humans is the interaction of 
digoxin, a Pgp substrate, with other drugs.  When administered a daily dose of verapamil 
(160 mg), a substrate and competitive inhibitor of Pgp, a 40% increase in plasma 
concentration and a reduction of renal elimination of digoxin were evident (Pedersen, 
1985; Verschraagen et al, 1999). In contrast, a 14-day St. John’s exposure led to a 
significant increase in fexofenadine clearance, consistent with Pgp induction (Moore et 
al., 2000).  
As an extremely persistent and toxic organochlorine, dieldrin readily 
bioaccumulates in fish, wildlife and humans (ASTDR 2002). Even though banned for all 
uses within the United States by EPA (U.S. EPA, 1971 and 1990), it still exists in all 
environmental media (U.S. Department of interior, 1999). Humans and animals are 
exposed to this compound though the food chain and direct contact (ASTDR 2002). 
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Studies have shown that dieldrin is a potent activator of human pregnane X receptor 
(PXR) (Coumoul et al, 2002; Lemaire et al., 2004), which is the main regulator for Pgp 
and CYP 3A4 expression (Veau et al., 2002; Matheny et al., 2004). In addition, chronic 
dieldrin treatment in rainbow trout alters hepatic disposition of [14C]-dieldrin and [3H]-7, 
12-dimethylbenz[a]anthracene (DMBA) (Gilroy et al., 1993 and 1996), and stimulate 
biliary excretion of [3H]-DMBA and [14C]-benzo[a]pyrene (Donohoe et al., 1998; 
Barnhill et al., 2003). These results, without induction of xenobiotic metabolizing 
enzymes, suggest that another mechanism, such as transport action, may be operative 
with these findings.  However, there is still no direct evidence pointing to interactions 
between dieldrin and Pgp. 
Little evidence exists regarding interactions between environmental contaminants 
and drugs via Pgp mechanisms, especially regarding the effects of contaminants on the 
pharmacokinetics and bioavailability of Pgp mediated drugs. We hypothesize that the 
pharmacokinetics and disposition of Pgp mediated drugs may be altered by contaminants, 
which inhibit or induce Pgp. The goal was to investigate the effects of dieldrin on the 
pharmacokinetics and disposition of tetracycline, a broad spectrum anti-bacterial drug.  
Specific objectives include: 1). to characterize the effect of dieldrin and tetracycline on 
Pgp transport activity at the bile canniculi using the prototypic Pgp substrate Rhodamine 
123 (Rho-123) in the isolated perfused liver preparation; 2). to evaluate the effect of 
diedlrin on biliary excretion of tetracycline and 3). to examine the effect of chronic 
exposure to dieldrin on the pharmacokinetics, distribution and excretion of tetracycline as 
related to Pgp expression. Tetracycline was chosen in this study for its structural 




























body (Aronson, 1980) and its widespread use in humans and animals. Tetracycline and its 
derivatives have been recognized as substrates of Pgp in bacteria (Levy, 1992, Chollet et 
al., 2004; Qin et al., 2004) and cultured cancer cells (Mealey et al., 2002). Studies have 
shown that the Pgp “like” transporter in fish displays a high degree of sequence 
homology (Chan et al., 1992), a similar tissue distribution pattern (Kleinow et al., 2000), 
and transport function consistent with that demonstrated in mammals (Schramm et al., 
1995). In the environment, fish are at high risk of being exposed to dieldrin and have 
shown a potential to retain dieldrin at high concentration levels in body (Jorgenson, 
2001). Catfish were used in this study due to use of tetracycline as a therapeutic in 
aquaculture applications (Plakas et al., 1998) and potential exposure to dieldrin. 
MATERIALS AND METHODS 
Chemicals 
Dieldrin (~90%) was obtained from Aldrich Chemical Company, Inc., 
Milwaukee, WI. [3H]-tetracycline (0.906 or 1.07 Ci/mM, >95%) was purchased from 
PerkinElmer Life Sciences, Inc., Boston, MA. Tricane methane sulfonate (MS-222) was 
provided by Argent Chemical Company, Redmond, WA. Dimethyl sulfoxide (DMSO) 
was supplied by Fisher Scientific, Fair Lawn, NJ. Tetrahydrofuran (C8H8O) was provided 
by Mallinckrodt, Inc., Pairs, Kentucky. Tissue Solubilizer TS-2 was acquired from 
Research Products International Corp., Mount Prospect, IL. Heparin sodium (1000 or 
10000 USP units/ml) was acquired from Elkins-sinn, Inc. Cherry Hill, NJ. 
Electrophoresis material and the Immuno-Blot™ Assay Kit with Goat Anti-mouse IgG 
Alkaline Phosphatase (GAM-AP) were provided by Bio-Rad Laboratories, Hercules, CA. 
The C219 murine monoclonal antibody was obtained from Signet Laboratories Inc., 
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Dedham, MA. Rhodamine-123 (Rho-123), tetracycline, verapamil, and all other 
chemicals used for buffer preparations were purchased from Sigma, St Louis, MO. 
Animals 
Male and female channel catfish used in these studies were obtained from the 
Louisiana State University Aquaculture Research Station, Baton Rouge, LA. Animals 
were grown and maintained at least 2 months prior to use under a flow-through 
conditions at 19oC in dechlorinated tap water with a 12 h light/dark photoperiod.  A 
commercial chow diet (Silvercup trout chow, Sterling Farms, UT) was fed at 0.5 to 1% 
body weight per day prior to use in experiments.    
[3H]-tetracycline (TET) Dose Preparations 
Solid [3H]-tetracycline (TET) (0.906 Ci/mmol or 1.07 Ci/mmol) as obtained from 
the manufacturer was diluted with 250 µl of DMSO to form stock solutions. The stock 
solutions were further diluted into [3H]-TET solutions (~16 µCi/ml) used in the in situ 
experiment, and solutions (52-63 µCi/ml) for in vivo investigations. 
Isolated Liver Perfusion Studies 
Surgery Procedure 
Catfish of both sexes were fasted 24 h prior to surgery. Isolated livers (19.02 ± 
5.01 g) were prepared according to the details previously described (Kleinow et al., 
2004). Animals were anesthetized with buffered Tricane methane sulfonate (MS-222) at 
induction and maintenance doses of 106 and 86 mg/l, respectively.  Following ventral 
midline and transverse incisions exposing the liver and gallbladder, the common bile duct 
was cannulated with a perforated PE260 tubing with an attached PE50 tubing for bile 
collections. Liver vessels were isolated and sutures preplaced. An intravenous catheter 
(13-gauge) was then inserted into the portal vein, ligated in place, and connected to a 
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gravity fed perfusion system supplying oxygenated and heparinized (10 USP/ml) teleost 
Ringer's solution ( 117.2 mM NaCl, 4.8 mM KCl, 0.9 mM CaCl2, 1.5 mM MgSO4, 12.3 
mM Na2HPO4, 1.4 mM NaH2PO4, 5 mM glucose, pH 7.4). Once media flow was 
established from the afferent cannula to the liver circulation, collateral vessels were 
ligated, the cardinal veins transected and the liver cleared of blood. After stabilization, 
the liver was removed from the fish while being perfused and placed on the perfusion 
apparatus. The perfusion apparatus was set at 12 cm of head pressure to create 
physiological pressures for oxygenated perfusate delivery during the experimental 
procedure. The isolated perfused livers were maintained at 20oC.   
Experiment Designs 
Eight groups of five to seven individual fish (1532.5 ± 311.5 g) were prepared for 
isolated liver perfusions in two separate experiments. In the first experiment to evaluate 
effects of tetracycline and dieldrin on Pgp transport activity, livers were pre-perfused 
with oxygenated teleost Ringers’ solutions (1L) containing vehicle alone for 1) control 
(N=5), or individual treatments 2) TET (20 μM) (N=5) or 3) dieldrin (20 μM) (N=7). 
This process removed the remaining blood and preexposed livers to specific treatment 
condition. Following pre-perfusion, the isolated livers were perfused in a recirculating 
system for 210 min with 250 ml of media, which were compositionally identical to the 
pre-perfusion mixture, except containing 1 μM Rho-123. A similar procedure was applied 
to the second experiment to examine effects of verapamil & dieldrin on transport of [3H]-
TET into bile. The treatment groups were: 1) control (N=6), 2) verapamil (20 µM) (N=5), 
3) dieldrin (20 µM) (N=5), using radiolabel [3H]-TET (8.8 nM) as analytes. Samples of 
bile and perfusate were harvested at 30 min intervals for the 210 min perfusion.  
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In Vivo Studies 
Dieldrin Treatment 
The effect of chronic dieldrin pretreatment upon Pgp expression and the 
pharmacokinetics and disposition of tetracycline were investigated in vivo in the catfish. 
All animals were acclimatized to experimental conditions for at least 2 weeks before 
dietary treatment. Control and experimental diets were prepared by coating commercial 
chow diet using tetrahypofuran (10 ml/kg diet) with or without dieldrin (10 mg/kg diet). 
Both stocks were made prior to the beginning of the experiments and stored at -20oC. All 
animals were fed diets with or without dieldrin (0.1 mg/kg body weight per day) at 1% 
body weight daily for 4 weeks prior to surgery.  
Dorsal Aorta Cannulation 
The cannulation procedure and animal maintenance after surgery were performed 
according to previous details (Kleinow, 1991). Following anesthetization, fish were 
weighed and placed in a dorsal recumbence on an aquatic operating table. The aortic 
cannula (PE-50 tubing) with an indwelling stylet was placed into the aorta along the 
dorsal midline of the fish’s mouth between the first and third branchial arches. The 
cannula was attached to the palate mucosa with preplaced sutures and brought dorsally 
through the cartilage rostral to the nares.  An extension of the cannula was anchored to 
the dorsal fin, and filled with heparinized saline (10 IU/ml, 0.9% NaCl). After surgery, 
fish were moved to individual holding chambers with flow-through water. Chamber 
design and cannula placement allowed for sampling from the free swimming fish. 




In Vivo Experiment Dosing, Design and Sample Collection  
Two separate experiments were used for in vivo investigations using cannulated 
animals. All animals (807.7 ± 93.7) of either sex were administered a single bolus dose of 
[3H]-TET at 20 µCi /kg body weight (8.31 µg/kg) through the preplaced aortic cannulas.   
The first experiment examined the pharmacokinetics of [3H]-TET with or without 
dieldrin (0.1 mg/kg body weight per day for 4 weeks) pretreatment using two groups of 
five or six fish. Following administration of [3H]-TET, 400 µl of blood samples were 
collected through the cannula at 1, 2, 4, 6, 8, 12, 24, 36, 48, 72 and 96 h after dosing. 120 
µl of blood samples were aliquoted and centrifuged for 10 min at 3000×g at 4oC. 50 µl of 
plasma aliquots were prepared for radioactivity measurements.    
The second experiment examined the tissue distribution and mass balance of [3H]-
TET as well as the hepatic expression of Pgp using two groups of five or six fish one with 
and one without dieldrin (0.1 mg/kg body weight per day for 4 weeks) preexposure.  At 
72 h after administration of [3H]-TET, fish were euthanized with MS-222 (250 mg/l) to 
harvest samples. Bile, liver, spleen, kidneys, heart, intestine, stomach, abdominal lipids, 
gills, muscle, eggs and carcass were collected and weighed for total mass balance and 
aliqots radioassayed for [3H]-TET molar equivalents in fish. In addition, intestine and 
stomach were cut open, inverted, contents rinsed with 0.9% saline; blotted, dried and 
homogenized before the sample was harvested and analyzed. The mass of the muscle 
tissue was assumed 50% of carcass in this study (Bosworth et al., 2001).  Aliquots of 
liver tissues (~ 2g) for Pgp expression analysis were harvested immediately following 
removal and mass balance, suspended in ice-cold modified Sack’s preservation buffer 
(5mM KH2PO4, 14 mM NaHCO3, 54mM K2HPO4, 5.9mM KHCO3, and 205 mM 
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mannitol, pH 7.4), snap frozen in liquid nitrogen and finally stored under -80oC until 
analysis.  
Rho-123 Assay 
Fluorescence of Rho-123 in bile and perfusate samples from isolated livers were 
measured with 20 nm slit width at excitation and emission wavelengths of 507 and 529 
nm, respectively, on a Hitachi F-2000 Fluorescent Spectrophotometer. Bile samples (20 
µl) or those less than 20 µl added zero time-point bile up to a volume of 20 µl, were 
diluted with teleost Ringer’s solution to a final volume of 600 µl. Each perfusate sample 
(20 µl) was combined with zero time bile (20 µl) and teleost Ringer’s solution to a final 
volume of 600 µl. Concentrations of Rho-123 was calculated in dilutions by interpolation 
upon a standard curve of Rho-123 concentrations formulated for each fish, using their 
individual zero time bile to minimize effects of different bile salt concentrations and 
compositions on fluorescence background. If the samples had reading outside of the 
standard curve range, they were diluted again up to a final volume of 600 µl, using teleost 
Ringer’s solution containing zero time bile (30:1, v/v).  
Radioactivity Measurements 
Tissue samples (50-100 mg) were digested in 0.5 ml of TS-2 Tissue Solublizer at 
50oC for 24 h. Following cooling, the samples were neutralized with 18 µl of glacial 
acetic acid and combined with 4.5 ml LSC -cocktail (Ultima Gold, Packard Bioscience, 
Meriden, CT). Bile, plasma or perfusate samples (20 µl) were not digested prior to adding 
4.5 ml LSC -cocktail. All scintillation samples were dark adapted overnight before 
counting. Samples were counted 30 min each on a Tri-Carb Liquid Scintillation Analyzer 
(Model 1900 TR). Quench correction, counting efficiency and background were 
performed for all samples.   
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Pgp Expression Analysis 
Plasma Membrane Protein Preparations    
Hepatic plasma membrane proteins were prepared as described by Doi et al, 2000. 
Hepatic tissue (~ 2 g) were homogenized in 16 ml of ice-cold plasma membrane buffer (5 
mM Tris–HCl, pH 7.5, 0.25 M sucrose, and 0.2 mM magnesium chloride), containing 1 
mM EDTA and 100 µl of protease inhibitor cocktail (Sigma, St Louis, MO).  The 
homogenates were centrifuged at 1000×g (Rotor type J25.50, Beckman) for 10 min at 
4°C and the resulting supernatant reserved. The pellets were resuspended in plasma 
membrane buffer and recentrifuged. Supernatants from both operations were combined 
and spun at 15 000×g for 20 min at 4°C. Resulting supernatants were centrifuged at 
100000×g in a TI 70 rotor for 1 h at 4°C. Final pellets containing the crude membrane 
fractions were resuspended in 1 ml of homogenization buffer. Hepatic membrane protein 
content was determined with folin phenol reagent (Lowry et al., 1951).  
Western Blot Analysis     
The membrane vesicles were subjected to gel electrophoresis, transfer to a 
nitrocellulose membrane, blocking and immunoblotting procedures for the detection of 
Pgp. Membrane vesicles (30 µg) were diluted (1:5) with sample buffer (62.5 mM Tris, 
pH 6.8, 2% SDS, 10% glycerol, and 0.001% bromophenol blue) and maintained at room 
temperature for 20 min. Proteins were loaded on a 7.5% acrylamide gel at a constant 
voltage of 200 V in running buffer (25 mM Tris–HCl, pH 8.3, 192 mM glycine, and 0.1% 
SDS running buffer), using Mini-protean™ II Dual Slab gel system (BioRad). After 
electrophoresis, proteins were transferred at 100 V for 2 h onto a 0.45 µg nitrocellulose 
membrane with transfer buffer (25 mM Tris, pH 8.3, 192 mM glycine, 20% v/v 
methanol). The membrane was then washed twice each for 5 min in Tris-buffered saline 
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(TBS) (20 mM Tris, pH 7.5, 500 mM NaCl) before blocked with 0.1 M Levamisole in 
TBS for 1 h. Following three 5-min washes in TBS, the membrane was blocked again 
with 3% gelatin in TBS solution and washed for 5 min using 0.05% Tween-20 in TBS 
(TTBS).  Membranes were then incubated overnight with Pgp C219 monoclonal antibody 
(Signet Laboratories Inc.) (0.2 µg/ml) in antibody buffer (1% gelatin in TTBS). 
Following two 5-min washes in TTBS, conjugate binding was performed with Goat Anti-
mouse IgG Alkaline Phosphatase (GAM-AP) for 90 min in antibody buffer. Following 
washes with TTBS and TBS, immunoreactivity was color developed using nitroblue 
tetrazolium in aqueous dimethylformamide with magnesium and 5-bromo-4-chloro-3-
indoyl phosphate. Molecular weight was determined with protein markers (Kaleidoscope 
Prestained Standards, Bio Rad Laboratories Inc.). The staining densities of protein 
immunoreactivity were quantified using a VersaDoc Imaging System (Quantity One, Bio 
Rad Laboratories Inc.). An internal standard sample was loaded in all gels for 
normalization of variability between gels.   
Pharmacokinetic Analysis 
The plasma concentration versus time course data obtained from administration of 
[3H]-TET in catfish was plotted on a semilogarithmic scale. Data were fitted by a two-
compartment, bolus-input, first-order output model (model 8), using PCNONLIN 3.0 
software (Statistical Consultants, Inc., Lexington, KY, USA). Line fitting for individual 
animal data was optimized using least-squares fit. Statistical moment theory was used for 
all subsequent pharmacokinetic determinations (Gibaldi and Perrier, 1982). The 
pharmacokinetic data were reported as mean ± SD. Whereas AUC = ∫096 Cpdt, Cp was 




The presented results are shown as the mean ± SD. All data were processed and 
graphed with Microsoft Excel 2003 (Redmond, WA).  Data analysis was performed with 
the statistical software SigmaStat for Windows (Version 1.0, Jandal Corporation, San 
Rafael, CA). One-way ANOVA was employed to examine significant differences at 
P < 0.05.   
RESULTS 
Effects of Tetracycline and Dieldrin on Pgp Transport 
The effect of tetracycline on Pgp transport activity was evaluated using in situ 
prepared, isolated perfused catfish liver preparation. The cumulative excretion of Rho-
123 (nM/kg body weight) into bile during 210 min isolated liver perfusions of 1 µM Rho-
123 is presented in figure 2.2. In the presence of 20 µM tetracycline, the cumulative 
biliary accumulation of Rho-123 (10.65 ± 2.45 nM/kg body weight) over 210 min was 
significantly less than that transported into bile by control livers (19.29 ± 5 nM/kg body 
weight) (p < 0.008). Tetracycline treatment resulted in a 45% decrease in biliary 
accumulation, as compared with Rho-123 alone.  
Similar to tetracycline, dieldrin decreased Rho-123 transport into bile in isolated 
perfused livers (Fig. 2.3). In the presence of 20 µM dieldrin, biliary accumulation of Rho-
123 during the 210 min liver perfusion was significantly lower (40%) than controls (p < 
0.011), with 210 min cumulative control and treatment values of 11.5 ± 1.75 nM/kg body 
weight and 6.80 ± 3.01 nM/kg body weight, respectively.  
Effects of Verapamil on Biliary Excretion of [3H]-TET 
The contribution of Pgp in the transport of [3H]-TET into bile was examined 



















































Figure 2.2 - Transport of Rho-123 into bile from isolated perfused catfish livers 
exposed 210 min to 1 µM Rho-123 with vehicle control or tetracycline (20 µM). Each 
column represents mean ± SD (nM Rho-123/kg body weight) for controls (n = 6) and 


























































Figure 2.3 - Transport of Rho-123 into bile from isolated perfused catfish livers 
exposed 210 min to 1 µM Rho-123 with vehicle control or dieldrin (20 µM). Each 
column represents mean ± SD (nM Rho-123/kg body weight) for controls (n = 5) and 
dieldrin treatments (TRT) (n = 7).  * = Significantly different from controls at p < 
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Figure 2.4 - Transport of [3H]-tetracycline (TET) into bile from isolated perfused 
catfish livers during 210 min exposure to 8.8 nM [3H]-TET with vehicle control or 
verapamil (VER) (20 µM). [3H]-TET equivalents transported into bile, expressed as 
pM/kg body weight. Each time point represents mean ± S.D. for controls (CTR) (n = 6) 
and VER treatments (TRT) (n = 5) (CTR: [3H]-TET; TRT: [3H]-TET + VER). * = 





preparations. Biliary accumulation of [3H]-TET equivalents (pM/kg body weight) from 
isolated perfused livers during exposure to 8.8 nM [3H]-TET with vehicle alone or 
verapamil (20 µM) is shown in figure 2.4. As compared with [3H]-TET alone, the amount 
of [3H]-TET equivalents transported into bile during verapamil treatment was lower at all 
time points. These differences increased over time, with significant differences evident 
between the two treatments at the 150, 180 and 210 min samplings (Control: 68.29 ± 
23.69; TRT: 40.35 ± 5.8) (p < 0.05).  At 210 min, bile accumulation of [3H]-TET 
equivalents in the presence of 20 µM verapamil (89.88 ± 7.5) was 34% lower than that 
with 3H-TET alone (135.29 ± 37.8) (p < 0.024).   
Effects of Dieldrin on Biliary Excretion of [3H]-TET 
Following a similar protocol, the effect of dieldrin on biliary excretion of [3H]-
TET was examined. Cumulative [3H]-TET equivalent transport into bile (pM/kg body 
weight) over time is presented with or without dieldrin (20 µM) (Fig. 2.5). As compared 
with vehicle alone (104.37 ± 16.96), the cumulative [3H]-TET equivalent content in bile 
during 210 min dieldrin treatment (50.43 ± 8.99) was significantly lower (p < 0.002).  
Not only was there an overall inhibitory effect on transport of [3H]-TET, but the rate of 
transport into bile was also reduced by dieldrin treatment. By 120 min, the amount of 
[3H]-TET equivalents transferred into bile during dieldrin treatment (6.69 ± 2.28) were 
significantly different from that with [3H]-TET alone (16.6 ± 9.20) (p < 0.05). These 
differences increased over time. At 210 min, dieldrin treatment resulted in a nearly 50% 
decrease in biliary excretion of [3H]-TET equivalents, a much greater decrease than 
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Figure 2.5 – [3H]-tetracycline (TET) equivalents transported into bile from isolated 
perfused catfish livers during 210 min exposure to 8.8 nM [3H]-TET with vehicle 
control or dieldrin (20 µM). Data are expressed as pM [3H]-TET equivalents/kg body 
weight and each time point represents mean ± SD for controls (CTR) (n = 5) and 
dieldrin treatments (TRT) (n = 5) (CTR: [3H]-TET; TRT: [3H]-TET + DIELDRIN). * = 







Effects of Dieldrin Pretreatment on In Vivo Pharmacokinetics of [3H]-TET 
Experiments were conducted to investigate the effects of dieldrin pretreatment 
(0.1 mg/kg body weight per day for 28 days) on the pharmacokinetics of a single 
intravascular dose of [3H]-TET (20 µCi/kg or 8.31 µg/kg body weight) (Fig. 2.6). Lower 
plasma concentrations of [3H]-TET equivalents were observed at all time points after 
dose administration in dieldrin-pretreated fish, as compared to the controls. Significant 
differences were detected 72 h to 96 h (p < 0.05) (Fig. 2.6). Pharmacokinetic parameter 
values as determined by the two compartment model for administration of a single 
intravascular dose appear in Table 2.1. The values obtained for AUC0-96 were 
significantly lower 27% in dieldrin treated fish (166.52 ± 26.98 h*ng/ml) than in the 
control animals (227.27 ± 50.81 h*ng/ml) (p < 0.05).  Consistent with the decreased 
AUC0-96, the value of the plasma clearance of [3H]-tetracycline in dieldrin pretreated fish 
(42.12 ± 6.82 ml/h) was elevated by 17% compared to that in controls (31.64 ± 6.21 
ml/h) (p < 0.035).  Significant differences were not observed for the half life of 
elimination (t1/2 kel) between two groups.    
Tissue Distribution and Mass Balance of [3H]-TET 
 [3H]-TET molar equivalents were widely distributed to most tissues of the catfish   
after the intravascular administration in both control and dieldrin treated groups (Table 
2.2). The highest concentrations of [3H]-TET equivalents were found in the bile, liver, 
kidneys and intestine. Concentrations of [3H]-TET equivalents in liver, kidneys, fat and 
eggs were significantly decreased at 72h post administration in the dieldrin pretreatment 
catfish, as compared to controls (p < 0.05). When mass balanced, the percentage of the 
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Figure 2.6 - Mean plasma [3H]-Tetracycline (TET) equivalent concentrations following 
a single intravascular administration of [3H]-TET at 20 µCi/kg body weight (8.31 
µg/kg) to catfish pretreated 4 weeks to a diet containing vehicle control (CTR) or 
dieldrin (0.1 mg/kg body weight per day) (TRT). Data are plotted upon a 
semilogarithmic scale and each concentration time point represents mean + SD (ng/ml) 
of five or six measurements (CTR: [3H]-TET; TRT: [3H]-TET + DIELDRIN). * = 













      
Value 
Parameter CTR TRT 
      
   
Alpha (α) (h-1) 0.587 ± 0.332 0.505 ± 0.233 
Beta (β) (h-1) 0.026 ± 0.002 0.031 ± 0.005 
A (ng/ml) 4.200 ± 0.667 3.555 ± 0.370 
B (ng/ml) 1.214 ± 0.479 0.981 ± 0.171 
t1/2(α)   (h) 1.474 ± 0.697 1.632 ± 0.730 
t1/2(β)   (h)       26.999 ± 2.494       22.812 ± 3.925 
kel (h-1)        0.099 ± 0.003  0.116 ± 0.026  
k12   (h-1) 0.355 ± 0.232 0.285 ± 0.160 
k21    (h-1) 0.158 ± 0.103 0.135 ± 0.057 
t1/2 kel   (h) 7.000 ± 0.188 6.214 ± 1.349 
AUC (h*ng/ml)      227.27 ± 50.81     *166.52 ± 26.98 
Volume (ml/kg)           381 ± 67            445 ± 44 
Cmax (ng/ml)      22.465 ± 4.689       18.823 ± 2.013  
Clearance (ml/h)        31.64 ± 6.21       *42.12 ± 6.82 
      
 
Table 2.1 - The values of Pharmacokinetic parameters obtained from two 
compartment analysis after a single intravascular dose of [3H]-tetracycline 
(TET) at 20 µCi/kg body weight (8.31 µg/kg) to channel catfish exposed 4 
weeks to a diet containing vehicle control or dieldrin (0.1 mg/kg body weight 







† The values of parameters are the mean ± SD of five or six measurements.   
† t1/2(α), half-life of [3H]-TET in plasma during distribution phase; t1/2(β), half-
life of  elimination phase; t1/2 kel , half-life of elimination; AUC, the area 
under plasma concentration time curve; Volume, volume of distribution; 













          
Concentration % of Dose 
Tissue/Bile ng/kg     
  CTR TRT CTR TRT 
     
Bile 1010.27 ± 883.1 905.94 ± 454.7 9.946 ± 5.741  11.048 ± 4.840 
Liver       4.44 ± 1.10        *3.19 ± 0.6 0.673 ± 0.142 0.554 ± 0.113 
Spleen 1.30 ± 0.87 1.37 ± 0.64 0.012 ± 0.006 0.013 ± 0.007 
Kidney 4.85 ± 0.45   *3.83 ± 0.31 0.325 ± 0.028  *0.265 ± 0.031 
Heart 1.75 ± 0.30  1.61 ± 0.42 0.012 ± 0.002 0.012 ± 0.003  
Intestine 3.33 ± 0.87 3.76 ± 1.34 0.331 ± 0.165 0.383 ± 0.102 
Stomach 1.41 ± 0.28 1.10 ± 0.37 0.145 ± 0.020  0.113 ± 0.034  
Fat 1.48 ± 0.05   *1.14 ± 0.17 0.028 ± 0.023 0.017 ± 0.010 
Gill 1.14 ± 0.17 1.04 ± 0.25 0.207 ± 0.013 0.195 ± 0.052 
Muscle 0.90 ± 0.33 0.66 ± 0.13 3.933 ± 1.389 2.979 ± 0.563 
Eggs 0.91 ± 0.22   *0.45 ± 0.08 1.505 ± 0.706 0.611 ± 0.338 
     
Tissue     
Accumulation   7.171 ± 1.855 *5.1.42 ± 0.803  
     
Total     
Accumulation    17.117 ± 6.14   16.190 ± 5.44 
          
     
Table 2.2 - Tissue concentrations and distribution of [3H]-tetracycline (TET) 
equivalents at 72h following a single intravascular administration of [3H]-TET at 
20 µCi/kg body weight (8.31 µg/kg) to channel catfish exposed 4 weeks to a diet 
with or without dieldrin (0.1 mg/kg body weight per day) (CTR without dieldrin 













† Tissue accumulation is the sum of distributions of [3H]-TET equivalents in all 
tissues, including liver, spleen, kidneys, heart, intestine, stomach, fat, gill, 
muscle and eggs, whereas total accumulation consists of  tissue accumulation 
and bile distribution.  
† Muscle compartment was assumed to be 50% of carcass in catfish (Bosworth 
et al., 2001).  
† Values are expressed as ng [3H]-TET equivalents/kg and data represents mean 





pretreatment resulted in a trend for increased accumulation of [3H]-TET equivalents in 
bile as percent of dose, but no statistical difference was detected between controls and 
treated group due to the high variability among fish. In contrast, the total accumulation of 
[3H]-TET equivalents as percent of dose in pretreated catfish tissues (5.142 ± 0.803), 
including liver, spleen, kidneys, heart, intestine, stomach, fat, gill, muscle and eggs, was 
significantly less (28%) than that in controls (7.171 ± 1.855) (p < 0.037). In the kidneys, 
distribution of [3H]-TET equivalents was significantly reduced 19% by dieldrin 
pretreatment (p < 0.008).  
 Hepatic Pgp Expression 
Pgp expression in hepatic plasma membranes from catfish following 4-week 
dietary exposure to vehicle control or dieldrin (0.1 mg/kg body weight per day) was 
measured. A 170 kDa C219 immunoreactive protein was observed in liver membrane 
preparations in both control and dieldrin treated fish (Fig. 2.7.B). Following dieldrin 
treatment, the level of staining density of immunoreactive Pgp in hepatic plasma 
membrane was significantly increased by 23%, as compared to that in controls (p < 
0.037) (Fig. 2.7.A).    
DISCUSSION 
The isolated perfused liver Rho-123/tetracycline and tetracycline/verapamil 
comparisons presented in these studies suggest that tetracycline is transported by Pgp or 
at least interacts with Pgp substrates. Tetracycline has been shown to be a substrate of 
Pgp homologues in bacteria and in cultured mammalian cells, however, there have been 
few comparative studies performed in the whole animal or perfused organs. 
Investigations performed in bacteria have demonstrated that multidrug resistance (MDR) 












































Figure 2.7 – A. Levels of C219 immunoreactive Pgp in the hepatic plasma membrane 
from catfish following 4-week dietary exposure containing vehicle control or dieldrin 
(0.1 mg/kg body weight per day). Data are expressed as relative staining intensity of 
antibody immuoreactivity for Pgp protein following standardization for inter-gel 
variability. Each column represents mean ± SD of five or six measurements. * = 
Significantly different from controls at p < 0.05. B. Western blot of Pgp protein in 







tetracycline, as compared to non-transfected bacteria (Levy, 1992; George et al., 1996; 
Chollet et al., 2004; Qin et al., 2004). Furthermore, cyclosporin A and verapamil, both 
competitive inhibitors of Pgp, completely reversed tetracycline resistance and increased 
accumulation of tetracycline in two human leukemic cell lines expressing Pgp (Kavallaris 
et al., 1993). These in vitro findings are consistent with the concept that tetracycline is a 
substrate of Pgp. Many prototypic substrates of Pgp, such as Vinca alkaloids, 
anthracyclines, epiodophyllotoxins, rhodamine dyes and doxorubicin share a ring 
structure similar to the four-ringed structure of the amphiphilic tetracycline (Fig. 2.1) 
(Argast and Beck, 1984; Lampidis et al., 1989; Germann et al., 1996; Sharom, 1997; 
Mealey et al., 2002). This structure and tetracycline’s physical properties appear to 
enhance partitioning into the cell membrane and the active interaction with Pgp (Bain et 
al., 1997). The transport mechanism which allows this broad substrate specificity has not 
been clearly defined. Pgp substrates, however, appear to share several common 
characteristics, including moderate hydrophobicity, amphiphilicity, low molecular 
weight, and a complex ring structure (Lampidis et al., 1989; Germann et al., 1996; Bain 
et al., 1997).  Pgp substrates have been shown to gain access to the binding site(s) of the 
Pgp transporter from the inner leaflet of lipid bilayer of the plasma membranes and 
interact with Pgp within the membrane rather than in the aqueous phase (Raviv et al., 
1990; Higgins and Gottesman, 1992; Sharom, 1997; Romsicki and Sharom, 1999).  
Tetracycline (20 µM) resulted in a 45% decrease in transport of Rho-123, a 
prototypic substrate of Pgp (Fig. 2.2), and verapamil (20 µM), a substrate and 
competitive inhibitor of Pgp, decreased the amount of [3H]-tetracycline transported into 
bile by 34% (Fig. 2.4) (Spoelstra et al., 1994; Saeki et al., 1993; Tsuji et al., 1993; Didier 
et al, 1995; Maki et al., 2003), during the 210 min isolated liver perfusions. Transport 
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studies suggest that inhibition of Pgp could result either from the competition of 
substrates at binding sites, from allosterical interactions by simultaneous binding to Pgp 
at different sites, or from blockage of ATP binding and hydrolysis process (Ford, 1996; 
Tamai and Safa, 1991; Ramachandra et al., 1998; Senior et al., 1995).  Like other classic 
competitive inhibitors, verapamil has been developed as an inhibitor to identify the 
potential for drug-drug interactions due to Pgp (Keogh and Kunta, 2006). In the current 
study, verapamil was employed as an inhibitor to examine the contribution of Pgp to 
excretion of [3H]-tetracycline into bile. Taking into consideration the limited duration of 
exposure, the appreciable decrease in [3H]-tetracycline equivalent movement into bile, 
these results suggest that Pgp transport plays a significant role for biliary excretion of 
[3H]-tetracycline. These findings are consistent with the concept that tetracycline acts as a 
substrate, a competitive inhibitor or by altering Rho-123 binding/transport by interacting 
at another site. While the exact mechanism is unknown, tetracycline appears to interact 
with Pgp transport.   
Interactions of xenobiotics with Pgp are complex. A number of organochlorine 
compounds, including DDT, DDD and DDE, when dosing occurs at 20 µM have been 
shown to reduce the efflux transport of the prototypic Pgp substrate Rhodamine B (1 µM) 
from the gills in the marine mussel M. galloprovinvialis (Galgani et al., 1996). Similarly, 
the current study, when using dieldrin (20µM), another highly hydrophobic 
organochlorine, observed decreased transport of Rho-123. In this case, transport of Rho-
123 (1 µM) into bile from isolated perfused livers was decreased 40% (Fig. 2.3). Other 
studies, however, have been obtained in vitro (using murine melanoma cell lines 
expressing human MDR1 gene) where the intracellular accumulation of the Pgp 
substrate, doxorubicin (50 µM), was not affected by DDT, DDE and dieldrin (100 µM) 
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(Bain and Leblanc, 1996). The inconsistency in response to these organochlorine 
compounds could be related to the different organchlorine concentrations, concentrations 
of Pgp substrates used to detect Pgp inhibition, or the duration of exposure.  
Several studies have demonstrated that dieldrin inhibits the ATPase system 
involved with Mg2+, Ca2+, Na+-K+ pumps on the plasma membrane in the fish and rabbit 
(Akera et al., 1971; Desaiah and Koch, 1975; Bandyopadhyay et al., 1982; Mehrotra et 
al., 1988). As an ATPase inhibitor, the inhibitory action of dieldrin upon Pgp transport of 
Rho-123 and [3H]-tetracycline in the current study may result from the reduction of 
ATPase activity. Other studies have reported that ATPase inhibitors, including the 
flavonoid quercetin and 5,7,3′,4′,5′-pentamethoxyflavone (PMF), inhibited Pgp transport 
by interfering with the basal and substrate-stimulated ATPase activity (Shapiro and Ling, 
1997; Choi et al., 2004). Therefore, dieldrin may alter ATPase system on the plasma 
membrane (Verma et al., 1978) and hence block the active transport of Pgp substrates 
through the cell membrane as a noncompetitive inhibitor.  
As seen with substrate-metabolizing enzymes, efflux transport activity of Pgp on 
the cell membrane may be saturated at elevated Pgp substrate concentrations (Lin, 2003). 
In contrast, the influx of these compounds into the cell by diffusion would not exhibit 
concentration based limitations other than those already imposed by the physiochemical 
characteristics of the compound and the membrane. In this situation, as the substrate 
concentration increases, the impact of Pgp efflux on intracellular accumulation is 
quantitatively less important (Lin, 2003). To explain these discrepancies, it is plausible 
that even though Pgp inhibition occurs at lower concentrations, it may not significantly 
affect the intracellular accumulation of this Pgp substrate at higher concentrations. This 
phenomenon may contribute to the apparent dichotomy between [3H]-tetracycline 
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disposition at high dieldrin doses used in the perfusion studies (inhibit movement into 
bile) and the latter chronic dieldrin exposures which facilitated [3H]-tetracycline 
elimination. 
Alternatively, different findings may result from the use of different species, cell 
lines, ectera between the current and past studies. Contrasting results were observed with 
in vitro studies in mussel gills examining DDT, DDD and DDE, and polychlorinated 
biphenyl--Aroclor 1254 as inhibitors for Pgp transport. These compounds acted as 
inhibitors in one species of mussel (Mytilus galloprovincialis) (Galgani et al., 1996), but 
did not appear to affect Pgp transport activity in another species (Mytilus californianus) 
(Cornwall et al., 1995).  A difference in the size of the Pgp-like protein reacting to C219 
monoclonal antibody in these two species was observed (Galgani et al., 1996). It remains 
to be clarified whether such disagreement results from concentration, species or other 
experimental differences.   
The foregoing studies suggest that tetracycline is transported by Pgp and dieldrin 
may influence Pgp transport activity. Acute high dose dieldrin exposures resulted in 
marked inhibitory effects on the biliary excretion of [3H]-tetracycline equivalents. 
Tetracycline equivalent transport was decreased by dieldrin (50%) to a greater extent than 
observed for verapamil (34%). In addition, a significant decline in transport was achieved 
earlier during dieldrin treatment than with verapamil. These results suggest that dieldrin 
acts as a more potent inhibitor of Pgp than verapamil. Inhibition of Pgp by dieldrin 
slowed down clearance of tetracycline from the liver into bile and prolonged intracellular 
residence time of tetracycline in the liver. Since biliary excretion is an important pathway 
for the elimination of tetracyclines out of fish (Plakas et al., 1988), these results would 
suggest that dieldrin co-exposure would result in decreased transport of tetracycline into 
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bile, and perhaps decreased clearance from the animal. Unpredictably and in contrast to 
the inhibitory effects of dieldrin (20 µM) on transport of [3H]-tetracycline into bile, 
chronic dieldrin pretreatment resulted in significantly lower mean plasma concentrations 
at 72 h and 96 h post administration (Fig. 2.6), a 27% decrease in the AUC0- 96h, and a 
17% increase in the plasma clearance of a single and subsequent dose of [3H]-
tetracycline, as compared to controls (Table 2.1). These alterations were coincided with a 
23% increase in hepatic Pgp expression in dieldrin treated fish (Fig. 2.7), which may 
contribute to the enhanced clearance and elimination of [3H]-tetracycline equivalents. 
Regulation of Pgp expression in response to inducers has been extensively studied in 
vitro and in vivo (Kliewer et al., 1998; Moore et al., 2000; Staudinger et al., 2001; 
Mikamo et al., 2003). DDE has been shown to increase expression of Pgp in the gill 
tissues of the mussel Mytilus californianus (Eufemia and Epel, 2000).  Induction of Pgp 
by dieldrin treatment as seen in the current in vivo studies with catfish would be 
consistent with literature findings. 
Previous studies showed that chronic dieldrin exposure stimulated biliary 
excretion of [14C]-dieldrin, [3H]-DMBA and [14C]-BaP in rainbow trout (Gilroy et al., 
1993; Donohoe et al., 1998; Barnhill et al., 2003), and  an apparent increase of Pgp-
related immunoreactivity in liver sections as detected by the C94 monoclonal antibody. 
The C219 and JSB-1 anti Pgp monoclonals, however, did not show similar differences 
(Curtis et al., 2000). Differences in sensitivity and specificity of antibodies reacting to the 
Pgp protein may have contributed to these observed inconsistencies in Pgp-related 
responses in the rainbow trout liver. The current study showed a significant induction of 
hepatic C219 reactivity in catfish following comparable dietary dieldrin treatment. The 
disparity in Pgp-related responses between the current study and the previous Curtis 
 83
study (Curtis et al., 2000) may be attributed to species differences in response to the Pgp 
inducer (Lin, 2003). Cytotoxic drugs, including adriamycin, daunomycin and 
mitoxantrone, and the polycyclic aromatic hydrocarbon, 3-MC, induced expression of the 
MDR gene in rat and mouse hepatocytes, with little inductive effect on human cells 
(Fardel et al., 1996; Chin et al., 1993). The activation of Pgp also occurs at the post-
translational level. Studies have shown that phosphorylation of serines and threonines on 
Pgp protein increased drug resistance activities in mammalian cell lines (Ratnasinghe et 
al., 1998). The activation of Pgp at the post-translational level is expected to elevate the 
transport ability of Pgp rather than expression of the MDR gene (quantity of Pgp protein). 
As an inducer of Pgp, dieldrin may involve different mechanisms to regulate expression 
of Pgp and activation of Pgp in different species (fish). While these mechanisms are 
possibilities, it remains to be clarified whether such disagreements result from dosage, 
detection methods, the length of xenobiotics exposure, experimental conditions, or other 
experimental differences (Doi et al., 2001).   
Mechanisms by which dieldrin exposure altered the pharmacokinetics of 
tetracycline may include not only induction of Pgp, but also by changes in the 
biotransformational enzymes, especially CYP450s. Several studies have demonstrated 
that dieldrin activated PXR and the constitutive androstane receptor (CAR) in mammals 
to induce CYP3A and CYP2B family enzymes (Coumoul et al., 2002; Wei et al., 2002; 
Lemaire et al., 2004). However, in rainbow trout, the increased biliary excretion of [14C]-
dieldrin, [3H]-DMBA and [14C]-BaP following chronic dieldrin treatment was not 
correlated to enzyme induction (Gilroy et al., 1993; Donohoe et al., 1998; Barnhill et al., 
2003).  No significant differences in total hepatic CYP450s, glutathione S-transferase, 
UDP glucuronosyltransferase and sulfotransferase activities were evident with dieldrin 
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exposure (Gilroy et al., 1993; Barnhill et al., 2003). Immunoblot analysis also revealed no 
change in expression of hepatic CYP isozymes (Gilroy et al., 1996). In addition, the 
biliary metabolite profile of [14C]-BaP was not significantly altered following dieldrin 
exposure in vivo (Barnhill et al., 2003). These findings suggest that induction of 
metabolizing enzymes by dieldrin treatment is unlikely in fish. On the other side, 
tetracycline undergoes minimal metabolism and is not biotransformed to a significant 
extent in animals (Aronson, 1980). Therefore, induction of Pgp may well be the most 
important factor in alterations of the pharmacokinetics of [3H]-tetracycline in the current 
study. These studies support the concept that Pgp induction contributed to these 
alterations. 
Following a single intravascular dose of [3H]-tetracycline (20µCi/kg; 8.31µg/kg), 
tetracycline molar equivalents (parent and metabolites) were widely distributed to most 
tissues with the highest concentrations in the intestinal, hepatic and renal tissues of both 
control and dieldrin treated catfish (Table 2.2). These findings are comparable to previous 
studies with tetracycline (Plakas et al., 1988). Dieldrin has been shown to be readily 
absorbed and accumulate in liver, kidney, bone marrow and adipose tissues in the body of 
fish (Jorgenson, 2001). As dieldrin inhibited Pgp transport of [3H]-tetracycline into bile in 
the isolated perfused liver, dieldrin would be expected to inhibit Pgp transport of [3H]-
tetracycline in tissues of mutual distributions. However, concentrations of dieldrin in 
these tissues may be too low to inhibit Pgp transport activity in the current chronic 
exposure study. In  a previous study, a concentration of only about 1.8 nM (~ 0.7 ug/g 
tissues) of dieldin was achieved in the liver after dietary exposure to dieldrin at 0.324 
mg/kg body weight daily for six weeks in rainbow trout (Barnhill et al., 2003). Although 
a different species was used in the current study, a lower dosage (0.1 mg/kg body weight 
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per day) and a shorter exposure period (4 weeks) may have resulted in a lower 
concentration of dieldrin in the liver of exposed catfish. At such a concentration, dieldrin 
may not have resulted in significant inhibitory effects on Pgp transport since Pgp 
inhibition is concentration-dependent (Lin, 2003). Even though Pgp inhibition by dieldrin 
may have occurred in the chronic dieldrin exposed fish, the inhibition would be much 
smaller than that observed in the isolated perfused liver. The Pgp inductive effect 
following chronic dieldrin exposure would mask these inhibitory effects.   
Pgp is constitutively located on the bile canalicular membrane of hepatocytes, the 
brush-border epithelial cells of the intestine, and the luminal side of renal proximal 
tubules (Cordon-Cardo et al., 1990; Schinkel et al., 1996; Balayssac et al., 2005;). 
Induction of Pgp may alter tissue distributions and excretion of Pgp substrates (Table 
2.2).  Consistent with previous findings in the rainbow trout studies, dieldrin pretreatment 
resulted in greater excretion of [3H]-tetracycline equivalents in bile at 72 h after dosing 
with a single administration. However, significant differences from the controls were 
probably hid by large variability among fish. In addition, the inductive effects of Pgp may 
also occur in the kidneys as well as intestine, leading elevated excretion of [3H]-
tetracycline into urine and the intestinal lumen. Compatible to increased excretion of 
[3H]-tetracycline,  the total accumulation of [3H]-tetracycline in pretreated catfish tissues, 
including liver, spleen, kidneys, heart, intestine, stomach, fat, gill, muscle and eggs, was 
significantly lower than that in controls, perhaps as a cumulative effect of Pgp induction.  
In current study, chronic dieldrin led to a decrease in tissue concentrations and 
systemic exposure of tetracycline in fish. Drug-drug interactions with Pgp induction are 
of concern for attenuated therapeutic effects of drugs in clinical treatment (Lin, 2003). In 
the aquatic environment, fish may be constantly exposed to various contaminants 
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including dieldrin-like compounds and Pgp induction may occur in response to the 
contaminant body burdens (Bard, 2000). Few studies exist regarding influence of 
environmental contaminants on therapeutic effects of drugs in fish or the involvement of 
Pgp induction. The current study provides information that suggests chronic contaminant 
exposure may be a determinant factor for therapeutic effects of drugs used in fish.   
In summary, this study provides results consistent with tetracycline as a substrate 
of Pgp and a competitive inhibitor of Rho-123 transport into bile of the isolated perfused 
liver of catfish. In addition, dieldrin inhibited biliary transport of Rho-123 and 
tetracycline. In contrast, chronic dieldrin exposure resulted in increased elimination of 
[3H]-tetracycline, as evidenced by a decrease in AUC, reduced tissue concentrations, and 
an increase in the whole body clearance. In dieldrin treated fish, induction of Pgp in 
hepatic plasma membranes may be responsible for alterations of the pharmacokinetics 
and disposition of [3H]-tetracycline. Cumulatively, these results suggest dieldrin has the 
potential to inhibit Pgp transport of tetracycline at the high concentrations with an 
inductive effect upon Pgp expression predominating at the low concentration chronic 
exposures in vivo. Dieldrin co-exposure would result in altered disposition of 
tetracycline, leading to toxicities and potential misdosing; whereas multidrug resistance 
may follow induction following chronic dieldrin exposure. 
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CHAPTER 3: ENHANCED BIOACCUMULATION OF 
IVERMECTIN AND BENZO[A]PYRENE IN CATFISH BY 





Fish are widely consumed by humans as a healthy low fat, protein rich, 
micronutrient and omega-3 (n - 3) fatty acid enhanced food (Daviglus et al., 2002). Over 
the past several decades a large number of studies suggest that fish effectively 
bioaccumulate and in some cases biomagnify select contaminants from the environment 
(Bryan, 1979; Clarkson, 1995). Consumption advisories have been issued for eating fish 
from impacted waters and for specific species of fish occupying higher trophic niches 
[U.S. Environmental Protection Agency (EPA) 2004].  Compounds such as mercury, 
polychlorinated biphenyls (PCB), DDT, and polycyclic aromatic hydrocarbons (PAHs) 
have received much of this attention. Recently the list of compounds which may enter the 
human food chain via fish has been expanded to include a variety of pharmaceuticals 
(Hastein et al., 2006). Drugs have entered waterways and fish by aquaculture practices, 
runoff from concentrated animals feeding operations and municipal sources (Daughton 
and Ternes, 1999).  
The risk of contaminants in the aquatic environment to the fish consuming public 
is dependent on the uptake or bioavailability of contaminants to the fish, the 
bioaccumulation of contaminants in the fish to be consumed and the bioavailability of the 
contaminants from a fish meal to the human consumer. A variety of factors are known to 
influence bioavailability and bioaccumulation of contaminants in fish (Leblanc, 1995; 
Ivanciuc et al., 2006). Notably, compound exposure, lipophilicity and the susceptibility of 
the chemical to biotransformation, play an important role in dictating contaminant body 
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burdens. Recently, studies in mammals suggest that Phase III transport processes by ABC 
transporter such as P-glycoprotein (Pgp) and multidrug resistance-related proteins (Mrp) 
have a significant effect on drug bioavailability from the intestine (Kurata et al ., 2002; 
Liu and Hu, 2000; Fromm, 2000) and in compound elimination from the body (Shitara, 
2006). Likewise, fish have been shown to have ABC “like” efflux transporters in 
excretory pathways as well as routes of bioavailability such as the intestinal mucosa 
suggesting similar roles of these “like” transporters in compound disposition and 
bioavailability. 
Contaminants found in the aquatic environment often exist as mixtures with other 
compounds (Yang et al., 1998). The interactions of components in mixtures have been 
shown to result in synergistic, antagonistic or additive effects on aquatic organisms 
(Altenburger et al. 2003). Surfactants, common environmental pollutants and mixture 
components in aquatic systems (Ahel et al., 1993; Todorov et al., 2002), generally exhibit 
a low order of direct toxicity to aquatic organisms; however, several studies are 
suggestive of interactive effects of surfactants upon the bioavailability and disposition of 
other compounds (Mann, 1962; Solon, et al., 1969; Pärt et al., 1985).  Studies examining 
strategies to inhibit the involvement of ABC transporters in cancer multidrug resistance 
have examined surfactants as a means to inhibit Pgp and Mrp’s contribution to this 
phenomenon (Kabanov et al., 2002). Initial indications suggest that surfactants may 
enhance membrane permeability (Drori et al., 1995; Hendrich and Michalak, 2003) or 
inhibit transporter efflux action directly (Woodcock et al., 1992; Nerurkar et al., 1996; 
Miller et al., 1999; Regev et al., 1999; Alqawi and Georges, 2003).  These activities may 
increase effective chemotherapeutic levels in cancer cells.  
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This study addresses experimentally two hypotheses. First, is that the C18 linear 
alkylbenzene sulfonate (LAS) surfactant at environmental concentrations can inhibit the 
efflux activity of Pgp “like” transporters in the bile canniculi of the catfish liver. A 
second hypothesis is that the C18 LAS surfactant at environmental levels, through its 
action on Pgp and/or membrane permeability, can influence xenobiotic bioavailability or 
bioaccumulation. The widely used veterinary pharmaceutical ivermectin and the PAH 
and environmental contaminant benzo[a]pyrene (BaP) were selected as model 
compounds based on their possible involvement with ABC transporters, environmental 
relevance and their limited bioaccumulation.  
MATERIALS AND METHODS 
 
Chemicals 
 3H-Ivermectin (IVM) was purchased from American Radiolabeled Chemicals, 
INC., St Louis, MO. 3H-Benzo[a]pyrene (BaP) was obtained from GE Healthcare UK 
Limited Amersham Place Little Chalfont Buckinghamshire HP79 NA, UK and BaP from 
Midwest Research Institute, Kansas City, MO. Methylene blue was obtained from Fisher 
Scientific Company, Fair Lawn, NJ. Tricane methane sulfonate (MS-222) was provided 
by Argent Chemical Company, Redmond, WA. Heparin sodium (1000 USP units/ml) 
was acquired from Elkins-sinn, Inc., Cherry Hill, NJ. Sodium dodecylbenzenesulfonate 
(C18 LAS) (~80%), rhodamine-123 (Rho-123), ivermectin (IVM), sodium tetraborate, 
chloroform, and all other chemicals used for buffer preparations were supplied by Sigma, 
St Louis, MO. 
Animals 
 
  Channel catfish, Ictalurus punctatus, were obtained from the Louisiana State 
University Aquaculture Research Station, Baton Rouge, LA, USA. Animals were grown 
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and maintained under a 12 h light/dark photoperiod in laboratory tank supplied with 
flow-through tap water. Water was dechlorinated and maintained at ~18oC. All fish were 
acclimated for one month prior to use in the experiment.  
In Situ Hepatic Rho-123 Disposition Studies 
Surgical Procedure  
Catfish of both sexes were fasted 24 h prior to surgery. The surgical preparation 
and perfusion of isolated livers were performed as previously described (Kleinow et al., 
2004). Animals were anesthetized with MS-222 at induction and maintenance doses of 
106 and 86 mg/l, respectively. The liver, gall bladder and hepatic portal vein were 
exposed by the ventral midline and transverse incisions posterior to the pectoral girdle.  
Following collection of residual bile and ligation of common bile duct, the gall bladder 
was cannulated in the apex with a PE260 tubing for subsequent bile collections. The 
portal vein and collateral vessels afferent to the liver were isolated, and ligatures were 
loosely placed around each. The portal vein was cannulated using a Quick-cath 14G 
cannula filled with heparin anticoagulant. Once ligated in place, oxygenated and 
heparinized (10 USP/ml) teleost Ringer's solution (117.2 mM NaCl, 4.8 mM KCl, 0.9 
mM CaCl2, 1.5 mM MgSO4, 12.3 mM Na2HPO4, 1.4 mM NaH2PO4, 5 mM glucose, pH 
7.4) was continuously perfused into the afferent cannula. Collateral vessels were rapidly 
tied off, and the efferent hepatic vein was cut at the level of the cardinal sinus to establish 
flow through the liver. Upon completion of perfusion circuit, the liver was transiently 
blanched, removed from the animal and placed on a perforated platform of a temperature 
controlled recirculation perfusion apparatus. Head pressure was maintained at 12 cm to 
create physiological pressures for media perfusion during the experiment. Livers were 
pre-perfused with oxygenated teleost Ringer’s solution (1L) containing vehicle alone for 
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control or individual treatments at temperatures dictated by the individual experiments. 
This process removed remaining blood and preexposed livers to specific treatment 
conditions.    
Isolated Liver Perfusion of Rho-123 
To examine the influence of LAS on hepatic disposition of the Pgp prototypic 
substrate Rho-123, six groups of five fish (1999.5 ± 447.9 g) were prepared for the in situ 
isolated liver perfusions. The six treatments included control, three LAS treatments (1, 5, 
and 20 μM) maintained at 18 °C, and two additional controls perfused at 23 °C and 28 
°C, respectively. The 23 °C and 28 °C experiments served as positive controls for 
changes in fluidity. Following pre-perfusion, livers were perfused in a recirculating 
system for 210 min with 250 ml of media, which were thermally and compositionally 
identical to the pre-perfusion mixture, except containing 1 μM Rho-123. Samples of bile 
and perfusate were collected at 30 min intervals for 210 min for fluorometric analysis.   
Once liver perfusions were completed, the liver was removed and weighed. Two 
aliquots of liver were snap frozen in liquid nitrogen and stored at -80 °C in the phosphate 
buffer for extraction of Rho-123 (see below) and in the buffer A  for membrane fluidity 
studies (see below), respectively.   
Extraction of Rho-123 
To determine the amount of Rho-123 remaining in liver after in situ isolated liver 
perfusions, Rho-123 extraction was performed according to the published methods 
(Sweatman et al., 1987). The liver tissue for each fish was blotted dry, weighed, and 
homogenized in 2 volumes of ice-cold phosphate buffer (100 mM Na2HPO4 and 
NaH2PO4, pH 8.5). A 3-mL aliquot of the homogenate was transferred into a silicone-
coated and capped tube prior to incubation at 4 oC for 30 min. Samples were extracted 3 
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times with 7 ml of freshly prepared ethyl acetate:1-butanol (9:1, v/v) and centrifuged 
each time at 510xg (IEC Centra CL3 Centrifuge) for 3.5 min. Organic phases of Rho-123 
extraction were combined in silicone-coated tubes, evaporated to dryness under a stream 
of nitrogen and  reconstituted in 5 ml methanol before fluormetric analysis. The aquatic 
phases were centrifuged for 12 min at 110xg (Beckman Microfuge 11). The resulting 
supernatants were transferred into fresh tubes, and spun. The supernatants from the 
second spin were used for fluorescent assay. Rho-123 concentrations were measured on a 
fluorescent spectrophotometer described as below except that the standard curve was 
prepared by diluting stock Rho-123 solutions (2 mg/100ml) with methanol. 
Membrane Fluidity 
 
Hepatic Membrane Vesicle Preparations 
 
In order to determine LAS influence on membrane fluidity, hepatic membrane 
vesicles were prepared and subjected to fluorescent anisotropy measurements according 
to the method from Kleinow et al. 2006. Hepatic tissues (2 g) were homogenized in 10 
volumes of ice-cold buffer A (12 mM Tris, pH 7.4, 300 mM Mannitol, 5 mM EGTA) and 
centrifuged at 12,000g for 5 min at 4 °C (Rotor type JA 25.50, Beckman). The pellet was 
discarded while the supernatant was spun at 48,000g for 15 min at 4 °C (Rotor type Ti 
70, Beckman). The second pellet was resuspended in buffer and centrifuged again under 
the same conditions. The pellet from the third spin was suspended in 500 µl of storage 
buffer (50 mM Tris-HEPES, pH 7.5, 0.1 mM MgSO4, 200 mM KCl, 125 mM D-
Mannitol, 5 mM EGTA), which were aliquoted, snap frozen in liquid nitrogen and stored 
at −80 °C until fluorescence anisotropy analysis. Hepatic membrane protein content was 
analyzed using folin phenol reagent with bovine serum albumin as a standard (Lowry et 
al., 1951).   
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Membrane Fluidity Measurements  
Fluidities of hepatic plasma membranes were detected by measuring fluorescence 
anisotropy (inverse of membrane fluidity) with the fluorescent probe, 1, 6-diphenyl-1,3,5-
hexatriene (DPH, Molecular Probes, Eugene, OR) at the corresponding temperature 
(Houpe et al., 1996). Fluorescence polarizations studies were carried out at λEX = 362 nm, 
λEM = 428 nm and slit width = 2 mm, using a spectrofluorometer (model FL3-22TAU3, 
Spex Fluorolog-3, Jobin Yvon-Spex, Edison, NJ) equipped with automated polarization 
accessory and two temperature regulated cell holders.  Samples of hepatic membrane 
vesicles, containing 150 μg protein in 50 μl storage buffer, were incubated with 8 μM 
DPH in a total volume of 3 ml incubation buffer (10 mM HEPES-Tris, pH 7.5, 200 mM 
KCl) for 30 min on ice.  After transferred into a cuvette, the sample was allowed to 
equilibrate for 10-15 min in the cell holders set to liver perfusion temperature. The 
fluorescence anisotropy (r) values were calculated according to the following equation: 
r = [Ivv−(Ivh×G)]/[Ivv+(2×Ivh×G)] 
where Ivv and Ivh are the fluorescence intensities detected with vertical and horizontal 
polarization of emission, respectively, when the excitation polarization is set in the 
vertical orientation (Houpe et al., 1996). G factors, ratios of spectrophotometer sensitivity 
for horizontal and vertical polarized light, were calculated as Ihv/Ihh where Ihv and Ihh are 
the fluorescence intensities detected with vertical and horizontal polarization of emission 
when the excitation polarization is set in the horizontal orientation (Lakowicz et al., 
1979). 
Effects of LAS on In Vivo Accumulation of 3H-IVM and 3H-BaP 
In these experiments, fish were individually housed in 15 L tanks supplied with a 
constant water flow of 80 ml per min. A peristaltic pump continuously transferred a 
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stable volume of the freshly prepared LAS solution into a mixed head tank supplied with 
a constant water flow, in which it was diluted to the appropriate final concentrations. 
LAS concentrations of test water were determined according to the published methods 
(Abbott 1962). Concentrated stock solutions (1000 mg/l) of C18 LAS were prepared 
every third day.   
To evaluate the effect of environmental relevant concentrations of LAS on the 
bioaccumulation of the pharmaceutical drug IVM and the pro-carcinogen BaP, six groups 
of fish (n=3 or 4, 701.1 ±135.4g) were exposed to LAS for 12 days at either 0, 100, or 
300 µg/l water. Starting on the 7th day of LAS exposure, catfish were administered 6 
daily doses of 3H-IVM (10 µg/day/kg body weight) or 3H-BaP (40 µg/day/kg body 
weight) by indwelling gavage tube in a slurry of semi synthetic diet.   
In order to facilitate multiple gavage administrations of 3H-IVM or 3H-BaP, fish 
were outfitted in dwelling stomach tubes 24 h prior to the six-day gavage administration. 
Following anesthetization, fish was weighed and placed with a dorsal recumbent position 
on operating table. The stomach tube was implanted and anchored to the cartilage 
rostrum of the nares (Kleinow, 1991). The experimental diet slurry was produced by 
mixing finely ground semi-synthetic diet with water (1:3). The appropriate amounts of 
3H-IVM (0.16 µCi/µg or 354.2 dpm/ng) in methanol or 3H-BaP (0.095 µCi/µg or 213.5 
dpm/ng) in toluene were then evenly dispersed over the slurry diet, which were 
thoroughly blended, evaporated under nitrogen and stored at −4°C until gavage 
administration. In addition, BaP diet was shielded from light and stored under nitrogen.     
Following six-day gavage administration, catfish were fasted for 24 h and 
euthanized with MS-222 (250 mg/l). Blood samples (~ 2 ml) were first collected from the 
caudal vein. Bile, gonads, abdominal lipids, liver, spleen, kidney, stomach, intestine, 
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muscle, gill and brain were then harvested and weighed for total mass balance and aliqots 
radioassayed for 3H-IVM or3H-BaP in the animals. In a similar fashion and purpose, 
intestines were cut open, inverted, contents rinsed out with 0.9% saline; blotted and dried 
before sample collected and analyzed. The volume of blood in fish was assumed to be 5% 
of total body weight while the mass of the muscle tissue was regarded as carcass in the 
mass balance determinations.   
Fluorescent Assay 
Fluorescence of Rho-123 in bile and perfusate samples from isolated perfused 
livers was measured at excitation and emission settings of 507 and 529 nm wavelengths, 
respectively, and 20 nm slit width, using a Hitachi F-2000 Fluorescent 
Spectrophotometer. Bile samples (20 µl) or those less than 20 µl added zero time-point 
bile up to a volume of 20 µl, were diluted with teleost Ringer’s solution to a final volume 
of 600 µl. Each perfusate sample (20 µl) was combined with zero time bile (20 µl) and 
teleost Ringer’s solution to a final volume of 600 µl. Concentrations of Rho-123 was 
calculated in dilutions by interpolation upon a standard curve of Rho-123 concentrations 
formulated for each fish, using their individual zero time bile to minimize effects of 
different bile salt concentrations and compositions on fluorescence background. If a 
sample had reading outside of the standard curve range, it was diluted again up to a final 
volume of 600 µl, using teleost Ringer’s solution mixed with zero time bile (30:1, v/v).  
Radioassay 
Tissues samples (~ 100 mg) and blood aliquots (100 µl) were digested at 50°C in 
0.5 ml of tissue solubilizer TS-2 (Research Products International Corp., Mount Prospect, 
IL) for 24 h.  Following cooling, the samples were neutralized with glacial acetic acid (18 
µL) and added to 4.5 ml of scintillant (Ultima Gold, Packard, Downers Grove, IL). Bile 
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samples (100 µl) were not digested prior to adding 4.5 ml of scintillant. All scintillation 
samples were dark adapted overnight before counting for 30min each with a Tri-Carb 
Liquid Scintillation Analyzers (Model 1900 TR). Quench correction counting efficiency 
and background were performed for all samples.   
Methylene Blue Active Substances Analysis for Measurement of Concentrations of 
LAS 
Concentrations of anionic surfactant LAS in the water were determined by the 
methylene blue technique (Abbott, 1962). 100 ml of water sample freshly collected were 
treated with alkalified methylene blue solutions. The anionic surfactant LAS reacts with 
the methylene blue active substance to form a chloroform soluble complex. The complex 
is extracted and dissolved in the chloroform phase by rapidly shaking the separating 
funnel for 1 min. The chloroform extract then passes through an acidified methylene blue 
solution to wash out inorganic anions associated with methylene blue substances, which 
have a low solubility in chloroform phase. The final chloroform extracts were measured 
by a spectrophotometer (U-2000, Hitachi) at a wavelength of 650 nm. Quantification was 
based on a four-point standard curve which was established from the results by treating 
100 ml of water samples containing suitable amounts of LAS (0, 10, 20 and 40 µg).  
Statistical Analysis 
All data were processed and graphed with Microsoft Excel 2003 (Redmond, WA).  
Data analysis was performed with the statistical software SigmaStat for Windows 
(Version 1.0, Jandal Corporation, San Rafael, CA). One-way ANOVA was employed to 





Effects of LAS on Biliary Excretion of Rho-123 
To investigate the effect of LAS on transport activity of Pgp, accumulation of the 
prototypic Pgp substrate, Rho-123, in bile was examined, using in situ prepared, isolated 
perfused livers.  As seen in Figure 3.1, the addition of LAS (1, 5, 20 µM) decreased 
movement of Rho-123 into bile in a concentration-dependent fashion. During the 210-
min liver perfusions the cumulative amounts of Rho-123 (nM/kg body weight) in bile 
were significantly decreased by 18.6 (12.35 ± 1.91), 38.1 (9.39 ± 1.40) and 66.7% (5.06 ± 
1.79) with increasing LAS concentrations at 1, 5 and 20 µM, respectively (p < 0.05).  
The effect of acute temperature change on biliary accumulation of Rho-123 was 
also evaluated. Temperature treatments of 23 oC and 28 oC as compared to controls (18 
oC) resulted in dramatic decreases in biliary excretion of Rho-123 by 90.4 (1.46 ± 0.41) 
and 93.7% (0.97 ± 0.45), respectively, during the 210-min perfusions (p < 0.0001).   
Effects of LAS on Hepatobiliary Disposition of Rho-123 
The distribution of Rho-123 in liver as parent and metabolites, bile and perfusing 
media, is shown with increasing LAS concentrations (Table 3.1). LAS at 1, 5 and 20 µM 
resulted in significant increases of Rho-123 retained in liver by 14.4 (65.39 ± 3.55 µg), 
20.0 (68.63 ± 3.67 µg) and 25.7% (71.85 ± 3.98 µg), respectively, as compared with 
control (57.16 ± 6.34 µg) (p < 0.05). This increased hepatic Rho-123 retention was 
exhibited primarily as significant increases in the organic parent fraction. In contrast, 
metabolites as aqueous Rho-123 in the liver was significantly decreased by LAS 
treatments at 1 and 20 µM, suggesting decreased metabolism of Rho-123 in the liver 
(Table 3.1). The increase in hepatic Rho-123 content was accompanied by decreased 



























































Figure 3.1 - Excretion of Rho-123 into bile from isolated perfused catfish livers 
exposed 210 min to 1 µM Rho-123 with vehicle control or LAS (1 µM, 5 µM or 20 
µM) at 18 oC, or vehicle alone treated at 23 oC or 28 oC. Each column represents 
mean ± SD (nM Rho-123 /kg body weight) (n = 5).  * = Significantly different from 















Table 3.1 - Effects of LAS on hepatobiliary disposition of Rho-123 at the end of 210-
min isolated liver perfusion of 1 μM Rho-123, coupled with vehicle or LAS at 1, 5 or 20 
μM at 18˚C, or with temperature treatments at 23˚C or 28˚C, respectively. 
         
                    Bile Excretion         Liver Extraction Media  Total 
     Total Aqueous Organic Total 
   μg/210 min    μg/whole liver weight μg/250 ml μg 
   
Control    14.31 ± 2.33   0.79 ± 0.29   57.16 ± 6.34    6.30 ± 1.58 78.56 ± 7.82 
   
1 μM LAS   *7.99 ± 1.45 * 0.34 ± 0.08 *65.39 ± 3.55    8.22 ± 1.14 81.94 ± 2.41 
   
5 μM LAS   *7.30 ± 2.22  0.57 ± 0.23 *68.63 ± 3.67    5.26 ± 0.37 81.75 ± 4.53 
   
20 μM LAS   *3.93 ± 0.66 * 0.39 ± 0.12 *71.85 ± 3.98    5.59 ± 1.35 81.75 ± 2.82 
   
Temp  23˚C  *0.95 ± 0.24 * 0.31 ± 0.05 *67.54 ± 4.93 *11.82 ± 1.64 80.63 ± 5.99 
   
Temp  28˚C  *0.67 ± 0.33 * 0.37 ± 0.18 *69.94 ± 3.94 *11.40 ± 1.35 82.38 ± 3.91 
         










† Data represents mean ± SD. of three or four measurements.  










temperature increases of 5 and 10 oC (23oC and 28oC) resulted in increased retention of 
Rho-123 in the whole liver by 18.2 (67.54 ± 4.93 µg) and 22.4% (69.94 ± 3.94 µg), 
respectively. These increases in hepatic Rho-123 retention were a result of significant 
increases of parent Rho-123 content (as detected in the organic fraction) and significant 
decreases in metabolites (the aqueous fraction) as compared to the control (p < 0.05). In 
addition, acute temperature treatments dramatically decreased Rho-123 equivalents found 
in bile and significantly increased Rho-123 retained in the media by 87.6 (11.82 ± 1.64 
µg) and 81.0% (11.40 ± 1.35 µg), as compared with the control (6.30 ± 1.58 µg) (p < 
0.01) (Table 3.1).   
Effects of LAS on Membrane Fluidity 
 In an effort to elucidate the mechanism by which LAS reduces Rho-123 
movement into bile of the isolated liver perfusions, a DPH fluorescence polarization 
study was performed. LAS treatments at 1, 5 and 20 µM resulted in significant decreases 
of anisotropies (inverse of membrane fluidity) in the corresponding hepatic membranes 
by 29.7 (0.102 ± 0.004), 32.4 (0.098 ± 0.005) and 38.6% (0.089 ± 0.003), respectively, as 
compared with control (0.145 ± 0.005) (p < 0.001) (Fig. 3.2). The most prominent 
decrease in anisotropy or increase in membrane fluidity was evident between control and 
the 1 µM LAS treatment, while fluidity continued to increase with LAS concentration, 
the changes were much smaller than the initial 1 µM treatment. Acute temperature 
increases of 5 and 10 oC (23 oC and 28 oC) also resulted in significant decreases in 
fluorescence anisotropy by 42.8 (0.083 ± 0.002) and 49.7% (0.073 ± 0.001), respectively 
(Fig. 3.2). These findings suggest membrane fluidity was altered with LAS exposure and 






































Figure 3.2 - Anisotropy of hepatic membrane vesicles prepared from isolated 
perfused livers, following exposure 210 min to 1 µM Rho-123 with vehicle control 
or LAS (1 µM, 5 µM or 20 µM) at 18oC, or vehicle alone maintained at 23oC or 
28oC.  Each column represents mean ± SD (n = 5).  * = Significantly different from 












Influence of LAS on In Vivo Accumulation and Disposition of 3H-IVM 
3H-IVM molar equivalent concentrations were significantly increased in blood 
and major individual organs including liver, kidneys, brain, gills, intestine, stomach, 
muscle, and eggs, with increasing LAS treatments (Table 3.2). LAS treatments of 100 
and 300 µg/l increased the dose remaining in fish at 24 hours after six daily consecutive 
dosings by 39.0 and 77.9% for 3H-IVM, respectively (Fig. 3.3). When considering the 
organ weight or volume, muscle, eggs and blood contributed the most to the composite 
increase with the muscle contributing 24.8 and 53.0% of the observed increase for the 
100 and 300 µg/l LAS dose, respectively. Concentrations of 3H-IVM equivalents 
increased 1.6- and 2.2-fold in blood, 1.3- and 1.6-fold in liver, 1.5- and 2.2-fold in 
kidney, 1.4- and 1.5-fold in intestine, 1.7- and 3.2-fold in brain, 1.4- and 1.8-fold in 
muscle with LAS exposure at the 100 and 300 µg/l, respectively. As presented in Fig. 
3.4, LAS treatments at 100 and 300 µg/l resulted in significant decreases of 26.7 and 
51.0% in the ratios of bile/blood concentrations and 20.7 and 28.0% in the ratios of 
liver/blood concentrations, respectively.  The decreasing bile/blood ratios with either 
LAS treatment were the result of significant increases in blood 3H-IVM in face of no 
significant change in movement into bile (Table 3.2). The liver exhibited a modest 
increase in 3H-IVM concentrations with LAS treatments. These 3H-IVM increases in the 
liver were less than those observed for blood resulting in decreasing liver/blood 
concentration ratios (Table 3.2). 
Influence of LAS on In Vivo Accumulation and Disposition of 3H-BaP 
LAS treatments lead to the increasing levels of 3H-BaP molar equivalents in 
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Figure 3.3 - Tissue distribution of 3H-IVM equivalents as per cent of dose 
following daily dietary administration of 3H-IVM at 10 µg/kg body weight to 
catfish for six days starting on 7th day during a twelve-day exposure to water alone 
(as control: CTR) or LAS at 100 or 300 µg/l. Each column represents mean ± SD 
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Figure 3.4 - Bile/blood and liver/blood 3H-IVM concentration ratios in catfish 
following daily dietary administration of 3H-IVM at 10 µg/kg body weight to catfish 
for six days starting on 7th day during a twelve-day treatment with water alone (as 
control: CTR) or LAS at 100 or 300 µg/l. Each column represents mean ± SD (n = 3 
















    
        
 
3H-IVM Equivalent Concentrations (ng/g)
      
 Tissues  CTR LAS 100 µg/L LAS 300 µg/L 
        
    
     Blood        10.72 ± 1.28      * 17.23 ± 1.44      * 23.81 ± 3.45 
     Bile      444.84 ± 59.51         459.29 ± 36.74       491.81 ± 108.85 
     Liver        52.74 ± 5.63     * 67.71 ± 2.59      * 85.75 ± 13.97 
     Spleen        10.48 ± 2.92        13.43 ± 0.9      * 22.26 ± 2.13 
     Kidney        28.46 ± 3.54     * 42.93 ± 3.04      * 61.39 ± 8.91 
     Heart        19.17 ± 6.12        20.82 ± 2.92      * 35.56 ± 8.28 
     Lipids        54.17 ± 12.73        55.94 ± 13.01         61.02 ± 20.07 
     Brain          9.83 ± 1.17     * 17.10 ± 4.25      * 31.29 ± 2.37 
     Gill        15.91 ± 1.16     * 21.66 ± 1.54      * 33.58 ± 6.25 
     Intestine          43.8 ± 4.80     * 61.87 ± 4.36      * 66.41 ± 3.63 
     Stomach        25.84 ± 2.91     * 34.96 ± 3.39      * 40.32 ± 7.49 
     Muscle          9.62 ± 0.84     * 13.68 ± 0.47      * 17.61 ± 0.63 
     Eggs        18.13 ± 2.46     * 25.31 ± 1.24      * 36.51 ± 2.91 
        
    
    
 † Values are expressed as ng 3H-IVM equivalents/g and data represents mean ± SD. of 
three or four measurements.  
* =Significantly different from controls (p<0.05). 
 
Table 3.2 - Tissue concentrations of 3H-IVM equivalents following daily dietary 
administrations of 3H-IVM at 10 µg/kg body weight to catfish for six days starting on 
7th day during a twelve-day exposure to water alone (as control: CTR) or LAS at 100 or 









doses recovered from the whole fish at 24 hours after consecutive dosings were increased 
by 50 and 157% with LAS exposure at 100 and 300 µg/l, respectively (Fig. 3.5).  This 
composite increase mostly came from contributions of intestine, muscle and liver.  With 
exposure to LAS at 100 and 300 µg/l, concentrations of 3H-BaP equivalents increased 
1.6- and 3.8-fold in liver, 1.7- and 4.3-fold in kidney, 1.3- and 1.7-fold in intestine, 2.0- 
and 3.9-fold in brain, 1.5- and 3.0-fold in muscle, 1.9- and 3.3-fold in eggs, respectively. 
Bile concentrations increased significantly 1.7- to 1.9-fold for the 100 and 300 µg/l LAS            
concentrations whereas liver concentrations increased 1.6- to 3.8-fold (Table 3.3). Blood 
exhibited concurrent concentration increases (Table 3.3).  Bile/blood concentration ratios 
were significantly decreased by 39.2 % only with LAS exposure at 300 µg/l. No 
significant change was noted for liver/blood 3H-BaP concentration ratios at either the 100 
or 300 µg/l LAS concentration (Fig. 3.6).  
DISCUSSION 
Surfactants are among the most common contaminants found in domestic and 
industrial wastewater and frequently occur with other contaminants as mixtures in the 
aquatic environment (Lewis, 1992; Yang et al., 1998). As one of the most widely used 
classes of surfactants, LAS has been found worldwide in a variety of aquatic 
environments at different concentrations. LAS has been detected in sewage effluents and 
in surface waters in the UK (1090 μg/l and 416 μg/l) (Holt et al., 1998; Fox et al., 2000) 
as well as in the effluents of wastewater treatment plants in the USA (4 to 94 μg/l) (Trehy 
et al., 1996). LAS has also been reported at concentrations of 20 to 1000 μg/l in outlets to 
estuaries and near-shore marine waters in the North Sea (Berna et al., 1991; Stalmans et 
al., 1991) and in Mississippi River water (0.1 to 2.8 μg/l) (Tabor and Barber, 1996). 
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Figure 3.5 - Tissue distribution of 3H-BaP equivalents as per cent of total dose 
following daily dietary administration of 3H-BaP at 40 µg/kg body weight to 
catfish for six days starting on 7th day during a twelve-day exposure to water alone 
(as control: CTR) or LAS at 100 or 300 µg/l. Each column represents mean ± SD 
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Figure 3.6 - Bile/blood and liver/blood 3H-BaP concentration ratios following daily 
dietary administration of 3H-BaP at 40 µg/kg body weight to catfish for six days 
starting on 7th day during a twelve-day exposure to water alone (as control: CTR) or 
LAS at 100 or 300 µg/l. Each column represents mean ± SD (n = 3 or 4). * = 























Table 3.3 - Tissue concentrations of 3H-BaP equivalents in catfish following daily 
dietary administrations of 3H-BaP at 40 µg/kg body weight for six days starting on 7th 








        
 
3H-BaP Equivalent Concentrations (ng/g) 
      
 Tissues  CTR LAS 100 µg/l LAS 300 µg/l 
        
    
     Blood          8.44 ± 0.98       * 14.75 ± 1.91      * 26.34 ± 1.33 
     Bile    1040.41 ± 155.96     * 1779.63 ± 291.68  * 1970.91 ± 147.24 
     Liver        92.25 ± 4.33   * 150.86 ± 10.92    * 349.68 ± 29.11 
     Spleen          7.94 ± 2.04        11.98 ± 3.50      * 18.51 ± 1.66 
     Kidney        38.03 ± 2.01     * 64.69 ± 14.88    * 162.71 ± 38.37 
     Heart          8.58 ± 0.68     * 16.10 ± 4.61      * 18.43 ± 1.55 
     Lipids          9.87 ± 2.53        14.75 ± 3.10      * 61.48 ± 12.24 
     Brain          5.10 ± 1.12     * 10.02 ± 2.08      * 20.02 ± 4.81 
     Gill        14.35 ± 1.79        30.98 ± 11.22      * 36.04 ± 8.55 
     Intestine      965.60 ± 62.97    1228.17 ± 186.37  * 1667.35 ± 363.2 
     Stomach        69.84 ± 33.06   * 203.28 ± 27.94    * 222.31 ± 73.98 
     Muscle          2.66 ± 0.46          4.07 ± 1.08        * 8.05 ± 0.80 
     Eggs          3.68 ± 0.44       * 7.11 ± 1.97      * 12.16 ± 0.29 
        
    
 
† Values are expressed as ng 3H-BaP equivalents/g and data represents mean ± SD. 
of three or four measurements.  








column due to limited degradation under anaerobic conditions (Ying, 2006).  A range of 
37 to 500,000 μg LAS /kg sediment (dry weight) have been reported (Bester et al., 2001; 
International Program on Chemical Safety, 1996; Jensen, 1999).  
Several early studies have suggested that surfactants enhance the bioavailability 
and alter the disposition of other compounds in fish (Mann, 1962; Solon, et al., 1969; Pärt 
et al., 1985). More up to date, investigations in the cancer treatment field have indicated 
that surfactants have the potential to override the transporter mediated multidrug 
resistance phenomenon exhibited by cancer cells (Orlowski et al., 1998; Bogman et al., 
2003; Regev et al., 1999; Drori et al., 1995; Hendrich and Michalak, 2003). The efflux 
action of such transporters in the intestine is now known to be an important modulator of 
bioavailability for a variety of orally administered drugs (Chan et al., 2004). In addition, 
the excipient actions of surfactants have been shown to increase drug bioavailability from 
the intestinal tract (Rege et al., 2002; Hugger et al., 2003). Collectively, these effects of 
surfactants have been reported to occur as a result of specific transporter inhibition (Rege 
et al., 2002; Orlowski et al., 1998; Bogman et al., 2003), membrane fluidization (Regev 
et al., 1999; Hugger et al., 2003), compound solubilization (Strickley, 2004) and cellular 
reentrance of effluxed compounds due to general increases in bidirectional membrane 
permeability (Drori et al., 1995; Hendrich and Michalak, 2003). The current study 
demonstrates that LAS inhibits the movement of Rho-123 into bile in the in situ prepared 
isolated liver preparation and increases at environmentally relevant concentrations the in 
vivo bioaccumulation of dietary 3H-IVM and 3H-BaP molar equivalents (parent and 
metabolites) in catfish. These latter data suggest that LAS at low concentrations, for 
which little overt toxicity is evident, may alter the exposure and bioaccumulation of other 
potentially hazardous chemicals to which fish may be co-exposed. Such mixture 
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interactions may augment exposure risk to not only the fish themselves, but also humans 
consuming those contaminated fish that may have higher than expected body burdens. 
 LAS treatment resulted in a concentration-dependent inhibition of Rho-123 
movement into bile of the in situ perfused liver (Fig. 3.1) and increased retention of Rho-
123 in liver tissues (Table 3.1). This increased compound retention in hepatic tissues was 
associated primarily with increases in parent compound and a significant, but small 
decline in formed metabolites. This latter finding is indicative of a limited, but 
measurable interaction of LAS with some facet of the biotransformation process. The 
nature of the interaction is unknown, but is likely to be associated with a membrane 
linked enzymatic system such as Cytochrome P450. Other studies have shown the effects 
of surfactants on biotransformation systems (Johnson et al., 2002; Batrakova et al., 2003 
and 2004). Importantly, the increases in parent compound retention in the liver while not 
stochiometrically related to the decrease in metabolites formed appeared to be primarily 
related to total declines in compound content in the bile. Since the total amount of Rho-
123 used and observed in the perfusion media were similar for all liver perfusion 
treatments, hepatic levels of Rho-123 increased with LAS treatment as would be 
expected with characteristic surfactant properties, and bile Rho-123 amounts dropped 
these results are most likely due to LAS effects upon permeability or transport function 
within the hepatocyte-biliary vectorial pathway rather than the amount of Rho-123 
accessing the hepatocytes from the perfusion media. 
 Membrane permeability and Pgp transport function are interdependent and for all 
practical purposes inseparable. The functional vectorial transport of substrates by Pgp has 
been clearly shown to be dependent on the passive permeability of the membrane to the 
transported substrate (Eytan et al., 1996 and 1997). Compounds considered to be non-
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transported modulators of Pgp activity have shown greater permeability and inward 
diffusability (Scala et al., 1997; Mülder et al., 1995). For these compounds, if transported 
by Pgp, movement is unrecognizable due to the membrane’s inability to maintain the 
gradient and prevent compound back-diffusion (Barnes et al., 1996; Fert’e, 2000). Under 
normal physiological conditions, Rho-123, a cationic Pgp substrate, demonstrates 
restricted membrane movement and vectorial transport (Yumoto et al., 2001; Speelmans 
et al., 1994; Heywang et al., 1998; James et al., 1977). The decrease in Rho-123 
movement into bile with LAS exposure may due to altered membrane permeability 
resulting from LAS-membrane interactions, by direct inhibition of Pgp transport or via 
alteration of the membrane environment around Pgp, therefore influencing transporter 
function. One of these alternatives or a combination at the apical hepatocyte bile interface 
may result in increasing accumulation of Rho-123 in liver and decreased biliary 
excretion.   
             Surfactants, as amphipathetic molecules, whose structures imitate that of 
glycerophospholipids, are able to insert themselves between lipophilic tails of membrane 
bilayers, resulting in disorder of the lipid-packing arrangement of membranes (Fert’e, 
2000). The net result is the membrane becomes fluidized, facilitating the passive 
diffusion of compounds (Lo, 2003), and increasing permeability (Drori et al., 1995; 
Hendrich and Michalak, 2003). In the present Rho-123 perfusion experiment, LAS 
exposure resulted in increased hepatic membrane fluidity. The fluorescence anisotropy 
measurements demonstrated a 29.7% decrease at the 1 µM LAS concentration and 
modest additional changes in membrane fluidity (inversely related to anisotropy) for the 
higher 5 and 20 µM LAS concentrations (Fig. 3.2). These changes in membrane fluidity 
with the 1 mM LAS treatment are likely to contribute to the increases in Rho-123 
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permeability. Membrane fluidity changes, especially with the higher LAS concentrations, 
were not stoichiometrically consistent with the concentration-dependent effects on Rho-
123 amounts transferred to the bile. The inconsistency here may be due to significant 
LAS dose dependent changes in Rho-123 permeability occurring over a small range of 
altered membrane fluidities once a critical point in gel /liquid phase transitions have been 
attained (Block et al., 1976). Currently, there is little evidence in the literature to support 
this concept. A second possibility is that the dose dependent decrease in Rho-123 
movement into bile with LAS is not merely the result of changes in membrane 
permeability as associated with increases in fluidity. From this perspective it is likely that 
Pgp as the efflux transporter of Rho-123 may be at least partially inhibited by LAS. It has 
been postulated that Pgp-interacting compounds exhibit characteristic surface-active 
properties such as the capability to partition into a membrane and modify the surface 
tension (Schinkel et al., 1996; Seelig, 1998). Clearly surfactants have these abilities. In 
fact a number of studies have suggested that amphipathic surfactants including Tween 80, 
Triton X-100 and Solutol HS-15 may be substrates or modulators of Pgp (Coon et al., 
1991; Zordan-Nudo et al., 1993). A likely conclusion for the present study is that LAS is 
competing with Rho-123 for transport. Although an attractive explanation, 
characterization of similar interactions for other classes of better-studied amphipathic 
lipophilic Pgp substrates and modulators have shown an array of relations including 
competitive, noncompetitive and mixed interactions. This mixed profile provides a great 
deal of uncertainty regarding their connection via a common transport site (Ayesh et al., 
1996). To add to the uncertainty both substrates and modulators stimulate Pgp ATP 
utilization and displace photoligand binding on Pgp (Dayan et al., 1997; Beck and Qian, 
1992; Liu and Sharom, 1996). A commonly cited hypothesis for these disparate results 
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suggests that Pgp has multiple sites, some independent of others, for compounds to 
interact with Pgp along its hydrophobic transmembrane domain (Ayesh et al., 1996; Boer 
et al., 1996). The actual mechanisms and interrelationships have yet to be defined. 
In the present study, acute temperature changes were used as a LAS free means 
for membrane fluidization (Kleinow et al., 2006) and as a comparison for the effect of 
LAS induced fluidity on transport of Rho-123 into bile. Acute increases of the perfusion 
media and isolated liver preparation temperature [5 and 10 oC (actual temperatures of 23 
oC and 28oC respectively)] resulted in 42.8 and 49.7% decreases in fluorescence 
anisotropy (increases in fluidity) (Fig. 3.2). This increase in fluidity almost completely 
abolished transfer of Rho-123 into bile (Fig. 3.1). One interesting observation is that the 
temperature increases resulted in hepatic Rho-123 levels in the same range as the LAS 
treatments, however, caused 5.9-11.9 fold lower Rho-123 levels in the bile. These results 
suggest that the hepatocyte to bile component of the pathway is preferentially affected 
and that greater fluidity may produce further declines in Rho-123 transport into the bile. 
Such findings are consistent with previous studies, which have found that acute 
incremental elevations in temperature increased membrane fluidity (Robertson and Hazel 
et al., 1999) along with intestinal membrane Rho-123 permeability and movement 
(Kleinow et al., 2006).  
It is useful to recognize that the anisotropy and hence fluidity measurements as 
reported here are composite readings associated with the whole isolated hepatocyte 
plasma membrane. As with other species, differences in membrane composition and 
fluidity exist for regional domains of the plasma membrane (Schachter and Shinitzky, 
1977) and with different cell types (Shinitzky and Inbar, 1976; Schulthess and Hauser, 
1995; Crockett and Hazel, 1995). Specific domains, which are more influential in 
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regionalized Rho-123 movement are possible.  Larger changes in membrane fluidity for 
specific domains with surfactants have been reported for fish (Zehmer and Hazel, 2003).  
Regardless of the mechanism of interaction it is of interest to note that even with 
the declines in bile levels of Rho-123 with LAS treatment, the bile concentrations when 
normalized on a volume to a weight basis with the liver and media, were much higher 
than both the liver and Rho-123 perfusion media concentrations suggesting that an active 
process was still operative (Table 3.1). Together with the thermal results these studies 
indicate that LAS and possibly other surfactants have the potential for greater fluidity 
effects on transport and highlight a potential synergy with acute temperature change. 
In the current study, LAS treatment increased the organ retention of all three 
compounds examined. For Rho-123 this was evaluated only in the liver while for the in 
vivo 3H-BaP and 3H-IVM experiments this finding was evident for all organs in the mass 
balance assessments. The increases in the compound concentration followed a dose 
response relationship with LAS exposure. This effect was generally greater for 3H-BaP 
than 3H-IVM or Rho-123 at comparable LAS concentrations. In the liver, increases in 
molar equivalent residues with LAS treatment over controls represented approximately 
14.4% for Rho-123, 18.1-20.0% (Concentration: 28.4-62.6%) for 3H-IVM and 71.6-
321.0% (concentration: 63.5-279.1%) for 3H-BaP. A similar phenomenon was observed 
for other organs in the in vivo studies for 3H-IVM and 3H-BaP. LAS increased 3H-IVM 
and 3H-BaP whole body molar equivalents 39.0% and 77.9% and 50 and 157%, 
respectively, for the 100 and 300 μg/l exposures. After considering organ weight and 
fluid volumes, muscle, eggs, and blood contributed disproportionably more to retention 
of 3H-IVM equivalents. For 3H-BaP equivalents, similar findings were evident for the 
intestine, muscle, and liver. These single point mass balance studies suggest that LAS 
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exposure at environmentally relevant concentrations result in altered residue amounts due 
to changes in disposition ultimately affecting toxicokinetics. What is particularly 
significant to note is that this effect was evident for all of these compounds of varying 
chemical characteristics, but the effects were greatest for a lipophilic compound seldom 
associated with Pgp transport.   
Different allocation patterns for Rho-123, 3H-IVM and 3H-BaP equivalents 
among the blood, liver and bile components of the hepatobiliary vectorial pathway 
suggest that LAS interactions may differ qualitatively or quantitatively with different 
compounds. LAS treatment decreased Rho-123 derived concentrations in bile, increased 
Rho-123 levels in the liver and maintained concentrations in media at near constant 
levels. Due to the chemical and transport characteristics of this compound these findings 
are likely to be due to the effects of LAS on Pgp transport function and / or permeability 
as described above. Increases in liver levels are likely to be related to reduction of Rho-
123 transport to the bile. On the contrary, upon LAS exposure, 3H-IVM molar 
equivalents exhibited little change in bile levels and significant increases in both the 
blood and liver 3H-IVM molar equivalent concentrations. The high bile to blood ratio of 
3H-IVM equivalents for the control is indicative of an active concentrating process. What 
is of interest is that the bile to blood ratio declined with exposure to both the 100 and 300 
LAS µg/l concentrations. This was a result of a very small increase in 3H-IVM 
equivalents in the bile in face of significant increases in blood concentrations. A similar, 
but less definitive finding (due to a moderate increase in liver IVM) was evident for liver 
/ blood ratios. This suggests that LAS influences 3H-IVM movement at the apical 
hepatocyte membrane and possibly the basal membrane. In addition, the significantly 
elevated blood levels suggest that LAS increased intestinal bioavailability, possibly 
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through excipient action or inhibition of Pgp in the intestine. LAS treatments lead to 
increasing levels of 3H-BaP molar equivalents in blood and major organs including liver, 
kidney, heart, eggs and stomach. A similar high bile to blood ratio was evident for both 
controls and the 100 µg/l LAS exposure suggesting that an active secretion of 3H-BaP 
equivalents into bile was evident. This could be contrasted with much lower liver/blood 
ratios. Such results strongly suggest while some compound equivalent preference 
occurred for the liver over blood it was much less pronounced than similar comparisons 
for bile. These results suggest that the major active concentration process was likely to 
occur on the apical canalicular interface. Although liver, bile and blood concentration 
increased with the increased 300 µg/l LAS exposure concentration (Fig. 3.3) the relative 
increase in bile concentrations were much smaller than the nearly proportional 3H-BaP 
equivalent concentration increases in liver and blood for control, 100 µg/l LAS and 300 
µg/l LAS exposures. The net result was a significant decline in the bile/blood ratio at 300 
µg/l LAS. A number of features may be operative. The increases in 3H-BaP equivalents 
for all components (bile, liver, blood) of the vectorial pathway at 100 µg/l LAS as well as 
maintenance of bile/blood and bile/blood ratios as seen for controls suggest that the 100 
µg/l LAS exposure increased intestinal bioavailability, or the total 3H-BaP equivalent 
amount in the pathway. At the 300 µg/l LAS concentration, the bile concentration 
increases modestly (89.4%) in comparison to blood (212.1%) and liver (279.1%). The net 
result is a significant decline in bile/blood ratios. What may cause this is unknown, but it 
is likely the higher LAS exposure not only facilitated greater intestinal permeability, but 
also curtailed effective biliary transport. The latter may be evident through direct 
transporter inhibition or an increase in apical permeability allowing compounds to back 
 126
diffuse to the hepatocyte. Both processes result in accumulation of 3H-BaP equivalents in 
liver, other organs and blood.  
At the intestine greater compound solubility, greater mucosal permeability or 
inhibition of retrograde ABC transporter efflux action, all potential mechanisms of the 
surfactant LAS, would contribute to greater xenobiotic availability following a downhill 
gradient from the intestinal lumen to the blood. On the elimination side enhanced 
permeability of the bile canniculi or proximal tubular membrane or inhibition of efflux 
transport action to the bile or urine would have the opposite effect. Less compound 
equivalents would be available for elimination as transporter inhibition would reduce the 
compound concentrating effect in bile or urine and increased permeability would 
facilitate a down hill reentrance of compounds back into the tissues. The net result of 
interactions at either one or both locations would be the same, accumulation of 
xenobiotics or their metabolites in the fish. The significance of these effects is dependent 
on a number of potential determinants including chemical characteristics, surfactant 
interactions with the membranes or transporters as well as the operative concentration 
gradients both at the intestine and elimination portals. The latter are likely to change with 
exposure history and even with the course of the elimination and digestive processes. The 
results presented for each Rho-123, 3H-IVM or 3H-BaP are consistent with varying levels 
of interplay between the effects of LAS on membrane permeability and transporter action 
at both the site of compound uptake (in vivo-intestinal bioavailability) and elimination.  
Compound molecular weight, charge, lipid solubility and perhaps the transporter 
involved in compound movement are likely compound specific features altering 
permeability or transport. For Rho-123 studies that increased intestinal bioavailability 
was not available for interaction because of the in situ experimental design. This 
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precludes direct comparison with in vivo studies, but also isolates the effect of LAS 
largely to the hepatocyte-bile vectorial pathway of elimination.   
Since membranes are amphipathic with both polar interfacial areas and a 
hydrophobic core, compounds transversing the plasma membrane or accessing Pgp in the 
inner leaflet must partition in the polar interfacial region of the membrane bilayer, 
partition and diffuse through the hydrophobic membrane core and desorb from the 
opposite interfacial region of the membrane.  This process does not appear to be 
determined solely by compound lipophicity, but appears to be influenced by other 
compound-membrane interactions in the various regions of the membrane such as 
electrostatic interactions, charge delocalization or screening, affinity for anionic lipids, 
dielectric constant and surface potential of membrane interface (Speelmans et al., 1994; 
James et al., 1977; Madden and Redelmeier, 1994; Webb et al., 1995; Mankhetkorn and 
Garnier-Suillerot, 1998; Fernández and Fromherz, 1977; Flewelling and Hubbell, 1986). 
Of the compounds examined, Rho-123 (mw: 469 g/mol), a moderately lipophilic cation, 
and IVM (mw: 875 g/mol), a moderately lipophilic neutral compound, have been shown 
to be substrates of Pgp (Yumoto et al., 2001; Schinkel et al., 1994). BaP (mw: 252 
g/mol), a more lipophilic neutral compound, is readily metabolized to a variety of anionic 
conjugates with characteristics consistent with Mrp substrates (Srivastava et al., 2002). 
For Pgp substrates which are lipophlic cationic compounds, such as Rho-123, high 
affinity for polar interfacial sites resulting from electrostatic interactions oppose 
movement to the opposite membrane leaflet. However, once compounds are in the 
lipophilic core the charge of the cation is delocalized or screened by lipophilic moieties 
allowing movement through the core. This initial restriction on the passive permeation 
process allows Rho-123 to be transported out of the cell of reducing accumulation. For 
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weak lipophilic bases the protonated form has high affinity for anionic lipids and the 
charge impedes diffusion. Neutral forms favored at lower pKa diffuses move rapidly. 
Proportions of the charged and uncharged forms at the membrane surface depend on pH 
and ionic compositions of aqueous phase and the dielectric constant and surface potential 
of membrane interface. In contrast lipophlic anions such as BaP conjugates diffuse more 
rapidly than similar featured cations, due to dipolar potential, have lower affinity for 
membranes and accumulate independent of Pgp activity.  
Compounds that exhibit some degree of lipophilicity and capability to cross 
membranes also display energetically unfavorable interactions with water in the aquatic 
environment. Water promotes partitioning of these types of compounds into organic 
sediments and living organisms including primary producers and consumers at the 
assorted trophic levels. Research has indicated that a primary means that these 
contaminants enter fish is via dietary transfer and for certain contaminants 
biomagnification along the aquatic food chain (Dietz et al., 2000). Factors that influence 
the efficiency and the amount of contaminants passed through food include the type and 
length of the food chain (Rasmussen et al., 1990; Broman et al., 1992; Cabana and 
Rasmussen, 1994), existing body burdens (Doi et al., 2000; Barber et al., 1991), the 
lipophilicity and size of the compound, exposure concentrations, bioavailability, 
biotransformation (Ivanciuc et al., 2006) and physical features such as temperature 
(Gewurtz et al., 2006). Fish represent a significant portal by which contaminants enter 
into the human diet. On a global and per capita basis fish are consumed in increasingly 
greater quantities (Hastein et al., 2006). As a high protein foodstuff consumption of fish 
has been publicized as providing healthful effects in preventing cardiovascular disease 
(Mori and Woodman, 2006; Breslow 2006), strokes (Bouzan et al., 2005), macular 
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degeneration (Seddon et al., 2006), dementia (Huang et al., 2005) as well as a variety of 
other disorders. For certain classes of contaminants such as organochlorines and 
polyaromatic hydrocarbons, consumption of fish has been estimated to account for as 
much as 65-90% of the existing human body burden (Fürst et al., 1992; Svensson et al., 
1995; Hattemer-Frey and Travis, 1991). Consistent with these findings correlations have 
been made between consumption patterns of contaminated fish and health effects 
including developmental and educational deficits in children (Mendola et al., 2005; 
Vartiainen et al., 1998; Faroon et al., 2001). 
Risk evaluation of chemicals in the environment must take in account the 
compound’s toxicity, persistence and bioaccumulation. For many environmental 
chemicals complete information is rare especially that regarding bioaccumulation in fish. 
In 2004, the UN established a directive requiring that information regarding compound 
bioaccumulation in fish must be available for each of the chemicals in production. The 
goal of this process is to identify compounds, which pose undue risk because of their 
bioaccumulation properties. Existing partitioning techniques using physicochemical 
characteristics such as lipophilicity, have identified compounds with the potential to 
bioaccumulate (Voutsas et al., 2002), however, these methods do not identify compounds 
for which bioaccumulation is significantly reduced by biotransformation.  Due to the 
thousands of compounds yet unevaluated and the potential restrictions placed upon 
targeted compounds, efforts are underway to develop in vitro and in silico techniques to 
accurately and cost-effectively predict bioaccumulation in light of a compound’s 
potential for biotransformation.  Conversely, factors that enhance bioaccumulation have 
not received much attention probably due to the complexity and unknown importance of 
the issue.   
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The abundant and widespread use of surfactants presents the opportunity for 
potential interactions with the mechanisms of disposition and toxicity for a multitude of 
other compounds in the environment. Degradation of surfactants discharged from 
municipal or industrial sources, is dependent on the time maintained under aerobic 
conditions (Kimerle et al., 1977; Kimerle, 1989; Karsa and Porter, 1995). This 
degradation process is significantly reduced for shorter intervals and under anaerobic 
conditions (Federle and Schwab, 1992; Prats-a et al., 2000). Anaerobic sediments often 
act as repository for elevated surfactant concentrations and many other contaminants 
(Westall et al., 1999; Federle and Schwab, 1992), support a variety of food chain 
organisms and provide a food chain exposure route from the contained contaminant 
mixture to the aforementioned organisms (Reynoldson, 1987; Casellato et al., 1992).  
Surfactants also enter the environment by actions associated with remediation of 
hazardous substances. Surfactants may be used in remediation of contaminated soils to 
facilitate compound recovery (Burchfield et al., 1994, Baran et al., 1998) as well as for 
aquatic based oil spills to disperse coalesced oil (Edwards et al., 2003; Harvey et al., 
1990). Such procedures can potentially bring significant amounts of surfactants, toxic 
compounds and components of the aquatic and human food chain together (Lewis, 1992).  
The current studies suggest that through alteration of permeability and transporter 
function, LAS may enhance bioavailability, alter distribution and /or limit dispositional 
processes so to increase bioaccumulation of mixture components. The possibility exists 
that surfactants will not only increase the levels of contaminants in fish, but also by so 
doing increase the subsequent exposure of humans. 
 In conclusion, these results suggest that LAS may influence the bioaccumulation 
of xenobiotics from environmental mixtures. LAS at environmentally relevant exposure 
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concentrations enhanced both oral bioavailability and decreased compound disposition 
over the time frame and sampling regimes examined. At this time it is unknown if the 
effects observed are representative, however, these results do occur for several 
compounds with different characteristics. Responses were not confined to known Pgp 
substrates. While these compounds all exhibit some degree of lipophilicity, it is uncertain 
what compound properties promote or conceivably enhance the effects observed. Initial 
indications suggest that variation in findings between compounds may result from 
differing contributions of altered permeability and transporter function both at the site of 
absorption and elimination.  However, the general response elicited for all compounds 
suggests that basic mechanisms, perhaps at the membrane may be involved. From the 
animal perspective, it is also of interest that waterborne LAS exposure influences uptake 
and disposition of dietary administered compounds.  At the environmental level it is 
unknown if such a response is more pronounced for certain organisms such as those 
associated with the benthos or if the response will be seen or even magnified at each level 
of the food chain. Full-scale bioaccumulation studies will be necessary to better evaluate 
the effects of LAS on this process.  These investigations will define the environmental 
and toxicological relevancy of these mixture interactions. 
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CHAPTER 4: SUMMARY AND CONCLUSIONS 
Fish in impacted environments are exposed a great number of contaminants as 
well as pharmaceutical agents as runoff from agriculture and used in aquaculture. The 
extent of systemic toxicity and biochemical effects of these compounds to fish and the 
fish consuming public is dependent on the uptake, bioavailability and bioaccumulation of 
these chemicals in fish. Therefore, understanding factors that influence bioavailability 
and bioaccumulation of these chemicals from the environment becomes essential in the 
determination of the effects of these compounds to fish and human health. Membrane 
permeability is a key determinant of absorption, distribution and elimination of chemicals 
in the body (Ayrton and Morgan, 2001). Recently, studies in mammals suggest the active 
membrane efflux mechanism of the ABC transporters P-glycoprotein (Pgp) and 
multidrug resistance related protein (Mrp) may limit absorption and facilitate elimination 
of drugs (Kurata et al ., 2002; Liu and Hu, 2000; Fromm, 2000). The studies presented 
here investigated the effect of the environmental contaminants, dieldrin, a persistant 
organochlorine pesticide, and linear alkylbenzene sulfonates (LAS), a surfactant, on Pgp 
transport and membrane permeability as related to the retention of two pharmaceutical 
drugs tetracycline and ivermectin (IVM) and the PAH and carcinogen benzo[a]pyrene 
(BaP). These compounds were selected based on indications of possible involvement 
with the mechanisms examined and environmental relevance. 
             Initial in situ experiments using isolated perfused liver preparations demonstrated 
that the antibiotic drug tetracycline decreased movement of the Pgp prototypic substrate 
Rhodamine-123 (Rho-123) into bile. This finding was consistent with tetracycline as a 
substrate as well as a competitive inhibitor of Pgp transport. Further, verapamil, a Pgp 
prototypic competitive inhibitor, resulted in a significant decrease in biliary excretion of 
 143
3H-tetracycline, providing further evidence that Pgp transport plays a role in the hepatic 
disposition and bioavailability of tetracycline. Biliary excretion is a key pathway for 
elimination of tetracycline from the body (Plakas et al., 1988).  Finally, the marked 
inhibitory effects of dieldrin on biliary excretion of Rho-123 and 3H-tetracycline were 
demonstrated. Dieldrin at 20 µM inhibited 3H-tetracycline transport to a greater extent 
than verapamil. These results suggested that dieldrin acted as a more potent inhibitor of 
Pgp than verapamil.    
In contrast to the inhibitory effects of dieldrin on transport of 3H-tetracycline into 
bile in isolated perfused livers, a chronic low-dose pretreatment of dieldrin (0.1 mg/kg 
body weight per day for 4 weeks) resulted in an increase in the plasma clearance as well 
as a decrease in tissue distributions and AUC0- 96h for administration of a subsequent 
single intra-aorta dose of 3H-tetracycline in catfish. These alterations were correlated 
reasonably well with an increase of Pgp expression in the liver tissues in dieldrin 
pretreated fish, which facilitated the clearance and elimination of 3H-tetracycline. These 
findings indicated that Pgp induction here may well be the most important factor for these 
alterations. Besides Pgp induction, induced metabolized enzymes may be involved to 
alter disposition and pharmacokinetics of tetracycline in fish. However, previous studies 
have shown that dieldrin-induced biotransformation enzymes were not observed in fish 
(Vodicnik et al., 1981) and tetracycline has been shown to undergo minimal metabolism 
in animals (Aronson, 1980). Therefore, these studies support the concept that Pgp 
induction contributed to these alterations of the in vivo disposition and pharmacokinetics 
of 3H-tetracycline.  
 Additional in situ studies examined the effect of the surfactant C18 LAS (1, 5, 
and 20 µM), including environmentally relevant concentrations, on the hepatobiliary 
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disposition of Rho-123 in isolated perfused livers. These studies demonstrated a 
concentration-dependent inhibition of Rho-123 movement into bile and increased 
retention of Rho-123 in liver tissues. The increased hepatic retention of Rho-123 was 
associated primarily with an increase in parent compound and a small decline in formed 
metabolites. The latter finding suggested that a limited, but measurable inhibition of 
biotransformation may occur. The increases in the parent compound in liver tissues 
appear to be related to the declines in compound content in bile. LAS treatment at the 1 
µM concentration resulted in a 29.7% decrease in fluorescence anisotropy (increased 
membrane fluidity) in the corresponding hepatic membranes, and modest additional 
changes at higher LAS treatments, which were not stoichiometrically related to changes 
in Rho-123 movement into bile. The inconsistency suggested that effects of LAS on Rho-
123 movement into bile are not merely the result of changes in membrane permeability as 
associated with increases in fluidity. It is likely that Pgp may be at least partially inhibited 
by LAS treatments. 
Sequential in vivo studies demonstrated that LAS at environmentally relevant 
concentrations (100 and 300 µg/L) resulted in elevated 3H-ivermectin (IVM) and 3H-
benzopyrene (BaP) molar equivalents remaining in catfish in a dose-response fashion. 
Concentrations of 3H-IVM and 3H-BaP equivalents in blood and major organs following 
dietary administration increased with increasing LAS concentrations in the water. After 
considering organ weight and fluid volumes, muscle, eggs and blood contributed 
disproportionably more to increased retention of 3H-IVM equivalents in catfish, while for 
3H-BaP equivalents, similar findings were evident for intestine, muscle and liver. In 
addition, different allocation patterns for 3H-IVM and 3H-BaP equivalents among the 
blood, liver and bile components of the hepatobiliary vectorial pathway were observed, 
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suggesting that LAS interactions may differ qualitatively or quantitatively with different 
compounds. These results were consistent with varying levels of interplay between the 
effects of LAS on membrane permeability and transporter action at both sites of 
compound uptake in intestine and elimination such as the bile. Compound molecular 
weight, charge, lipid solubility and perhaps the transporter involved in compound 
movement are likely compound specific features altering permeability or transport. 
In summary, these studies have shown that ABC transporters and/or membrane 
permeability play a critical role in disposition and bioaccumulation of xenobiotics in fish. 
Environmental contaminants may influence bioaccumulation and bioavailability of other 
compounds in environmental mixtures through different interactions with transporters 
and/or the plasma membrane. At the high concentrations, dieldrin appears to be a potent 
Pgp inhibitor, which decreased biliary elimination of Pgp substrates Rho-123 and 3H-
tetracycline. In contrast, inductive effects of Pgp predominated at the low dose of dieldrin 
with chronic exposure, which led to increased plasma clearance and decreased tissue 
distributions of 3H-tetracycline.  Studies with surfactants suggest that LAS at 
environmentally relevant concentrations altered membrane permeability and the efflux 
activity of Pgp in the isolated perfused liver and enhanced the oral bioaccumulation and 
curtailed compound elimination in catfish. These effects occurred for a variety of 
compounds with different characteristics. The importance of these later studies is that 
apparently innocuous compounds such as surfactants may enhance the bioaccumulation 
of more hazardous environmental contaminants in fish and hence in the human diet. 
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